var title_f7_46_7904="Tinel sign for ulnar neuropathy";
var content_f7_46_7904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinel's sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the elbow flexed at 90 degrees and the arm externally rotated, the medial epicondyle and the olecranon process are identified. With firm pressure the groove between the two bony prominences is tapped repeatedly with the tip of the finger. A positive tinel's sign should reproduce the lancinating pain or numbness felt in the fourth and fifth fingers. The response should be distinctly different from the opposite side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7904=[""].join("\n");
var outline_f7_46_7904=null;
var title_f7_46_7905="Early osteo";
var content_f7_46_7905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Early osteomyelitis in the metatarsal head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Soft tissue loss is seen overlying the 5th metatarsal head (asterisk). The underlying osseous structures are unremarkable. B) Three weeks later, a corresponding radiograph reveals cortical destruction of the 5th metatarsal head (white arrow). Subtle periarticular osteopenia seen about the 4th metatarsal-phalangeal joint (black arrows) represents one of the earliest discernable osseous changes associated with osteomyelitis and reflects contiguous spread in this case. Such changes may not be radiographically evident for the first 1-2 weeks following initial infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Perry Horwich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7905=[""].join("\n");
var outline_f7_46_7905=null;
var title_f7_46_7906="Incision site";
var content_f7_46_7906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incision site for thyroid and parathyroid surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Site of incision - 1 cm below cricoid. Surface anatomy with underlying anatomy shown to demonstrate why this location is optimal for thyroid and parathyroid surgery (underlying superior pole of thyroid and its blood vessels).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7906=[""].join("\n");
var outline_f7_46_7906=null;
var title_f7_46_7907="Photoallergic eruption 2";
var content_f7_46_7907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photoallergic eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 45-year-old woman developed an acute, well-demarcated, erythematous plaque with vesicles after topical application of ketoprofen gel followed by sun exposure. The patient wore socks which protected the foot from the sun, creating the line of dermarcation that is visible in the image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Eric Ehrsam, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7907=[""].join("\n");
var outline_f7_46_7907=null;
var title_f7_46_7908="Homatropine: Patient drug information";
var content_f7_46_7908=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Homatropine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/43/35508?source=see_link\">",
"     see \"Homatropine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/24/15747?source=see_link\">",
"     see \"Homatropine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Homatropaire;",
"     </li>",
"     <li>",
"      Isopto&reg; Homatropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an eye exam.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to homatropine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697208",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Down's syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear sunglasses. Sunlight may bother your eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12531 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-61DB87C3C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7908=[""].join("\n");
var outline_f7_46_7908=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179245\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016761\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016760\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016765\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016766\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016768\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016763\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016764\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016769\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016770\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/43/35508?source=related_link\">",
"      Homatropine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/24/15747?source=related_link\">",
"      Homatropine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_46_7909="Right bundle branch block 1";
var content_f7_46_7909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Complete right bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 142px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACOAegDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD13xa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg55x/Fr/8Sv8A4+Lz/kK6eeYOv+k2/J+Tr7ew4OediR/9f/pF5/r4zzB1+5yfk6+3sODnnNP3vu/rc9pR91afh/h/u/1+RI/+v/0i8/18Z5g6/c5Pydfb2HBzzj6M/wDxM/FH+kXn/IVh6wdf9GteT8nX29hwc87Ej/6//SLz/XxnmDr9zk/J19vYcHPOPoz/APEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzyN6r+unqFOOm3bp/h/u/1+WxI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzj+LX/wCJX/x8Xn/IV088wdf9Jt+T8nX29hwc87Ej/wCv/wBIvP8AXxnmDr9zk/J19vYcHPOP4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzyTfuv+v1ClH3o6dun+H+7/X5bEj/6/wD0i8/18Z5g6/c5Pydfb2HBzySP/r/9IvP9fGeYOv3OT8nX29hwc8kj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPJI/wDr/wDSLz/XxnmDr9zk/J19vYcHPNp/193mTGO2nbp/h/u/1+WPoz/8TPxR/pF5/wAhWHrB1/0a15Pydfb2HBzzsSP/AK//AEi8/wBfGeYOv3OT8nX29hwc84+jP/xM/FH+kXn/ACFYesHX/RrXk/J19vYcHPOxI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzEHp/Xf1KcdVp26f4f7v9flj+LX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzyJ+9939bgo+6tPw/wAP93+vyJH/ANf/AKRef6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP8ASLz/AJCsPWDr/o1ryfk6+3sODnnYkf8A1/8ApF5/r4zzB1+5yfk6+3sODnnH0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OeRvVf109Qpx027dP8P8Ad/r8tiR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x/Fr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg552JH/1/wDpF5/r4zzB1+5yfk6+3sODnnH8Wv8A8Sv/AI+Lz/kK6eeYOv8ApNvyfk6+3sODnkm/df8AX6hSj70dO3T/AA/3f6/LYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4OeSR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeSR/9f8A6Ref6+M8wdfucn5Ovt7Dg55JH/1/+kXn+vjPMHX7nJ+Tr7ew4OebT/r7vMmMdtO3T/D/AHf6/LH0Z/8AiZ+KP9IvP+QrD1g6/wCjWvJ+Tr7ew4OediR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x9Gf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeYg9P67+pTjqtO3T/AA/3f6/LH8Wv/wASv/j4vP8AkK6eeYOv+k2/J+Tr7ew4OediR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x/Fr/8AEr/4+Lz/AJCunnmDr/pNvyfk6+3sODnnYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4OeRP3vu/rcFH3Vp+H+H+7/X5Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzzj6M/8AxM/FH+kXn/IVh6wdf9GteT8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzzj6M/8AxM/FH+kXn/IVh6wdf9GteT8nX29hwc8jeq/rp6hTjpt26f4f7v8AX5bEj/6//SLz/XxnmDr9zk/J19vYcHPOP4tf/iV/8fF5/wAhXTzzB1/0m35Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc84/i1/+JX/x8Xn/ACFdPPMHX/Sbfk/J19vYcHPJN+6/6/UKUfejp26f4f7v9flsSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzySP/r/APSLz/XxnmDr9zk/J19vYcHPJI/+v/0i8/18Z5g6/c5Pydfb2HBzySP/AK//AEi8/wBfGeYOv3OT8nX29hwc82n/AF93mTGO2nbp/h/u/wBflj6M/wDxM/FH+kXn/IVh6wdf9GteT8nX29hwc87Ej/6//SLz/XxnmDr9zk/J19vYcHPOPoz/APEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc8xB6f139SnHVadun+H+7/X5Y/i1/wDiV/8AHxef8hXTzzB1/wBJt+T8nX29hwc87Ej/AOv/ANIvP9fGeYOv3OT8nX29hwc84/i1/wDiV/8AHxef8hXTzzB1/wBJt+T8nX29hwc87Ej/AOv/ANIvP9fGeYOv3OT8nX29hwc8ifvfd/W4KPurT8P8P93+vyJH/wBf/pF5/r4zzB1+5yfk6+3sODnnH0Z/+Jn4o/0i8/5CsPWDr/o1ryfk6+3sODnnYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4OecfRn/4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OeRvVf109Qpx027dP8P93+vy2JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55x/Fr/wDEr/4+Lz/kK6eeYOv+k2/J+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4Oecfxa/8AxK/+Pi8/5CunnmDr/pNvyfk6+3sODnkm/df9fqFKPvR07dP8P93+vy2JH/1/+kXn+vjPMHX7nJ+Tr7ew4OeSR/8AX/6Ref6+M8wdfucn5Ovt7Dg55JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55JH/1/wDpF5/r4zzB1+5yfk6+3sODnm0/6+7zJjHbTt0/w/3f6/LH0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OecfRn/4mfij/AEi8/wCQrD1g6/6Na8n5Ovt7Dg552JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55iD0/rv6lOOq07dP8P93+vyx/Fr/8Sv8A4+Lz/kK6eeYOv+k2/J+Tr7ew4OediR/9f/pF5/r4zzB1+5yfk6+3sODnnH8Wv/xK/wDj4vP+Qrp55g6/6Tb8n5Ovt7Dg552JH/1/+kXn+vjPMHX7nJ+Tr7ew4OeRP3vu/rcFH3Vp+H+H+7/X5Ej/AOv/ANIvP9fGeYOv3OT8nX29hwc84+jP/wATPxR/pF5/yFYesHX/AEa15Pydfb2HBzzsSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzj6M//ABM/FH+kXn/IVh6wdf8ARrXk/J19vYcHPI3qv66eoU46bdun+H+7/X5bEj/6/wD0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc8k37r/AK/UKUfejp26f4f7v9flsSP/AK//AEi8/wBfGeYOv3OT8nX29hwc8kj/AOv/ANIvP9fGeYOv3OT8nX29hwc8kj/6/wD0i8/18Z5g6/c5Pydfb2HBzySP/r/9IvP9fGeYOv3OT8nX29hwc82n/X3eZMY7adun+H+7/X5Y+jP/AMTPxR/pF5/yFYesHX/RrXk/J19vYcHPOxI/+v8A9IvP9fGeYOv3OT8nX29hwc84+jP/AMTPxR/pF5/yFYesHX/RrXk/J19vYcHPOxI/+v8A9IvP9fGeYOv3OT8nX29hwc8xB6f139SnHVadun+H+7/X5Y/i1/8AiV/8fF5/yFdPPMHX/Sbfk/J19vYcHPOxI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzj+LX/wCJX/x8Xn/IV088wdf9Jt+T8nX29hwc87Ej/wCv/wBIvP8AXxnmDr9zk/J19vYcHPIn733f1uCj7q0/D/D/AHf6/Ikf/X/6Ref6+M8wdfucn5Ovt7Dg55x9Gf8A4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OediR/9f/pF5/r4zzB1+5yfk6+3sODnnH0Z/wDiZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55G9V/XT1CnHTbt0/wAP93+vy2JH/wBf/pF5/r4zzB1+5yfk6+3sODnnH8Wv/wASv/j4vP8AkK6eeYOv+k2/J+Tr7ew4OediR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x/Fr/8AEr/4+Lz/AJCunnmDr/pNvyfk6+3sODnkm/df9fqFKPvR07dP8P8Ad/r8tiR/9f8A6Ref6+M8wdfucn5Ovt7Dg55JH/1/+kXn+vjPMHX7nJ+Tr7ew4OeSR/8AX/6Ref6+M8wdfucn5Ovt7Dg55JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55tP8Ar7vMmMdtO3T/AA/3f6/LH0Z/+Jn4o/0i8/5CsPWDr/o1ryfk6+3sODnnYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4OecfRn/4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OediR/8AX/6Ref6+M8wdfucn5Ovt7Dg55iD0/rv6lOOq07dP8P8Ad/r8sfxa/wDxK/8Aj4vP+Qrp55g6/wCk2/J+Tr7ew4OeSjxa/wDxK/8Aj4vP+Qrp55g6/wCk2/J+Tr7ew4OeSk3733f1uZVI+5HT8PKP90y/FOn3aacS3iTXZQdUsBh7W3AybiABuLcfMOoHQkDIIODqyaZefv8A/iqPEH+vjPNpbc/c5P8Ao/X29hwc8p4tf/iV/wDHxef8hXTzzB1/0m35Pydfb2HBzzsSP/r/APSLz/XxnmDr9zk/J19vYcHPIvi+7+tzdX5Vp+H+H+7/AF+WRJpl5+//AOKo8Qf6+M82ltz9zk/6P19vYcHPOVpWn3baj4kC+JNdUrqkIJFrb5c/Z7Y7mzb8MOgAwMKOCSSeskf/AF/+kXn+vjPMHX7nJ+Tr7ew4OecfRn/4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OeR7r+unqEL227dP8P8Ad/r8vPfiD4r8QeFfFWkaRFealex63epBaTvcW8LBx5IJkT7CcfM4xtLHAzjnB6nXrHURokT3viDWftDajp/mRLBA6K5ngBIb7MpJU8rkDO1cryQeG+OzZ+J3wsPm3Df8TrO5o8MP3lpyBtHPtjsOOefUvFr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg55Jr3X6f11M6Em6nK1tbovL+6LJpl5+/wD+Ko8Qf6+M82ltz9zk/wCj9fb2HBzySaZefv8A/iqPEH+vjPNpbc/c5P8Ao/X29hwc868j/wCv/wBIvP8AXxnmDr9zk/J19vYcHPJI/wDr/wDSLz/XxnmDr9zk/J19vYcHPNpf193mVG+mnbp/h/u/1+XJ6Vp922o+JAviTXVK6pCCRa2+XP2e2O5s2/DDoAMDCjgkknVk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnlNGf8A4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OediR/9f/pF5/r4zzB1+5yfk6+3sODnmIbf139Sne607dP8P93+vy5PxTp92mnEt4k12UHVLAYe1twMm4gAbi3HzDqB0JAyCDg6smmXn7//AIqjxB/r4zzaW3P3OT/o/X29hwc8p4tf/iV/8fF5/wAhXTzzB1/0m35Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc8i+L7v63BX5Vp+H+H+7/X5ZEmmXn7//AIqjxB/r4zzaW3P3OT/o/X29hwc85WlafdtqPiQL4k11SuqQgkWtvlz9ntjubNvww6ADAwo4JJJ6yR/9f/pF5/r4zzB1+5yfk6+3sODnnH0Z/wDiZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55Huv66eoQvbbt0/w/3f6/JZNMvP3/8AxVHiD/Xxnm0tufucn/R+vt7Dg55yvFOn3aacS3iTXZQdUsBh7W3AybiABuLcfMOoHQkDIIOD1kj/AOv/ANIvP9fGeYOv3OT8nX29hwc84/i1/wDiV/8AHxef8hXTzzB1/wBJt+T8nX29hwc8k/hf9fqFK/NHTt0/w/3f6/JZNMvP3/8AxVHiD/Xxnm0tufucn/R+vt7Dg55JNMvP3/8AxVHiD/Xxnm0tufucn/R+vt7Dg5515H/1/wDpF5/r4zzB1+5yfk6+3sODnkkf/X/6Ref6+M8wdfucn5Ovt7Dg55tL+vu8yY3007dP8P8Ad/r8uT0rT7ttR8SBfEmuqV1SEEi1t8ufs9sdzZt+GHQAYGFHBJJOrJpl5+//AOKo8Qf6+M82ltz9zk/6P19vYcHPPE+L59UXWLxLbWYrLRZtfiTUVmM8F1cj7LalI7YwqHMvDkIpDMUQAEFg2V8PfE+o/wDC4fFHhVbjWP7BjhhvraPU9811G3+jrndJucKwcsEbkfKMKdymILT+v8xSqcs4xa7dF2X93yOY1z4j+JG8cDwXewajFqjalagNJfWxiLB43R/lsg2CFVhxkZGUOCp9I8ZXfijR9S0+30m+1LUotRvo7ZGmnt7Z1k2GQsy/YmG1UiJ4bceyHvxn7TPh+4t/7O8e6LLcDVNGuoklleH7qAq0UhDYXKynG3aS3mAnha7X4e64/je8m8WMtxDYrDBaWI2MxEj+VJdnPlKGAdYYwecm3YjG4hqUVe9/6+8zjUlzeze+nReX93pbcxPiD4r8QeFfFWkaRFealex63epBaTvcW8LBx5IJkT7CcfM4xtLHAzjnBoHxnc+G/F19pnjPVdW0gahqEflX9u9rNbmRYIN/ml7ZHUqph5CBfmGR8rM0P7QMkw+Inwxe0Mk1yursYlnBiDNvtMZIQkc8cK2Bg7T3426urP4i/FwaN8RI7rw60F4JI9Mdd73MrxwxtEZxt27lhiZMIdwJAbJUlNXa/r9SVVcW46dLaLy/u/5H0VJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPOV4p0+7TTiW8Sa7KDqlgMPa24GTcQANxbj5h1A6EgZBBweskf8A1/8ApF5/r4zzB1+5yfk6+3sODnnH8Wv/AMSv/j4vP+Qrp55g6/6Tb8n5Ovt7Dg55U/hf9fqdNK/NHTt0/wAP93+vyWTTLz9//wAVR4g/18Z5tLbn7nJ/0fr7ew4OeSTTLz9//wAVR4g/18Z5tLbn7nJ/0fr7ew4OedeR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeSR/9f8A6Ref6+M8wdfucn5Ovt7Dg55tL+vu8yY3007dP8P93+vy5PStPu21HxIF8Sa6pXVIQSLW3y5+z2x3Nm34YdABgYUcEkk6smmXn7//AIqjxB/r4zzaW3P3OT/o/X29hwc8poz/APEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc8xDb+u/qU73Wnbp/h/u/wBflyfinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHB1ZNMvP3/8AxVHiD/Xxnm0tufucn/R+vt7Dg55Txa//ABK/+Pi8/wCQrp55g6/6Tb8n5Ovt7Dg552JH/wBf/pF5/r4zzB1+5yfk6+3sODnkXxfd/W4K/KtPw/w/3f6/LIk0y8/f/wDFUeIP9fGebS25+5yf9H6+3sODnnK0rT7ttR8SBfEmuqV1SEEi1t8ufs9sdzZt+GHQAYGFHBJJPWSP/r/9IvP9fGeYOv3OT8nX29hwc84+jP8A8TPxR/pF5/yFYesHX/RrXk/J19vYcHPI91/XT1CF7bdun+H+7/X5LJpl5+//AOKo8Qf6+M82ltz9zk/6P19vYcHPOV4p0+7TTiW8Sa7KDqlgMPa24GTcQANxbj5h1A6EgZBBweskf/X/AOkXn+vjPMHX7nJ+Tr7ew4Oecfxa/wDxK/8Aj4vP+Qrp55g6/wCk2/J+Tr7ew4OeSfwv+v1Clfmjp26f4f7v9fl558XvF2vfD+KG8S41nUtLuLhYzcGa1t2SYKGCshsz1VSQQf4TkDjdv+H5/Emt+DY9YTVL+K9vTb3NtamWBo2jdYmBeUWOVYAngIw4HJzmuh8caFb+K/CmtaHd3N2sV6VjDtbkhG+Qo5ACklWCnbkZ2gd+fAfg/repXGgXvwuv7ef7QmpiC6QcrDZFybtWKRtg5Qxg7wS1wuCNtXb+v6ZzucoSV1o7W0W+n909P+GF3q3ibRNS1e91LW9Kmu7+GYQIttPuQ29sUkZxbAbihUgADjbkE5z2cmmXn7//AIqjxB/r4zzaW3P3OT/o/X29hwc8poz/APEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc8zDb+u/qdGqtp26f4f7pyfinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHB1ZNMvP3/8AxVHiD/Xxnm0tufucn/R+vt7Dg55Txa//ABK/+Pi8/wCQrp55g6/6Tb8n5Ovt7Dg552JH/wBf/pF5/r4zzB1+5yfk6+3sODnlL4vu/rcFflWn4f4f7v8AX5ZEmmXn7/8A4qjxB/r4zzaW3P3OT/o/X29hwc85WlafdtqPiQL4k11SuqQgkWtvlz9ntjubNvww6ADAwo4JJJ6yR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55Huv66eoQvbbt0/w/wB3+vyWTTLz9/8A8VR4g/18Z5tLbn7nJ/0fr7ew4OecrxTp92mnEt4k12UHVLAYe1twMm4gAbi3HzDqB0JAyCDg9ZI/+v8A9IvP9fGeYOv3OT8nX29hwc84/i1/+JX/AMfF5/yFdPPMHX/Sbfk/J19vYcHPJP4X/X6hSvzR07dP8P8Ad/r8lk0y8/f/APFUeIP9fGebS25+5yf9H6+3sODnkk0y8/f/APFUeIP9fGebS25+5yf9H6+3sODnnXkf/X/6Ref6+M8wdfucn5Ovt7Dg55JH/wBf/pF5/r4zzB1+5yfk6+3sODnm0v6+7zJjfTTt0/w/3f6/Lk9K0+7bUfEgXxJrqldUhBItbfLn7PbHc2bfhh0AGBhRwSSTqyaZefv/APiqPEH+vjPNpbc/c5P+j9fb2HBzymjP/wATPxR/pF5/yFYesHX/AEa15Pydfb2HBzzsSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzENv67+pTvdadun+H+7/X5cn4p0+7TTiW8Sa7KDqlgMPa24GTcQANxbj5h1A6EgZBBwZ9ftNbtdI1G40jWtc1C/jkR4bSSO1gExGz5d5tSFb0yME4zgHNXfFr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg552JH/1/wDpF5/r4zzB1+5yfk6+3sODnkS977v63BX5Vp+H+H+7/X5eLfCjx9rfxFu9QENzqljZ2ksDXEjXNtK43527UWyAY5j7svUYDHg6uhX3iOf4leJtB+1amlnb3MF3c6gktuTh441iBiNnkyMI84BVQFI+YgF+D8Yt/wAKq+P1v4hikmi8P685+1yOnzLuZGn4IZsq/lzcKM5CjjNet/C+41S607XrzX/tVtqV5qyXUluISTCrwWxjjbMa/OkexDwMlOhzktpXX9fqY0ZyfutK630W11b7JvSaZefv/wDiqPEH+vjPNpbc/c5P+j9fb2HBzzleKdPu004lvEmuyg6pYDD2tuBk3EADcW4+YdQOhIGQQcHrJH/1/wDpF5/r4zzB1+5yfk6+3sODnnH8Wv8A8Sv/AI+Lz/kK6eeYOv8ApNvyfk6+3sODnlT+F/1+ptSvzR07dP8AD/d/r8lk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnkk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnnXkf8A1/8ApF5/r4zzB1+5yfk6+3sODnkkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OebS/r7vMmN9NO3T/D/d/r8uT0rT7ttR8SBfEmuqV1SEEi1t8ufs9sdzZt+GHQAYGFHBJJOrJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPKaM/wDxM/FH+kXn/IVh6wdf9GteT8nX29hwc87Ej/6//SLz/XxnmDr9zk/J19vYcHPMQ2/rv6lO91p26f4f7v8AX5cn4p0+7TTiW8Sa7KDqlgMPa24GTcQANxbj5h1A6EgZBBwStTxa/wDxK/8Aj4vP+Qrp55g6/wCk2/J+Tr7ew4OeSl9r7v63Mql+SOn4eS/umX4o8QWkunFVbXc/2pYP8+j3CggXEBJyYR83HA6k4ABJ51ZPEln+/wCfEH+vj66Lc8/c5P7jr6D2HBzyni1/+JX/AMfF5/yFdPPMHX/Sbfk/J19vYcHPOxI/+v8A9IvP9fGeYOv3OT8nX29hwc8tX5t+39bmqUeVaf17v93+vyyJPEln+/58Qf6+Protzz9zk/uOvoPYcHPOVpXiC0TUfEjM2ukSapC4xo9wTj7PbDLAQ/K3HAOCRg4IIz1kj/6//SLz/XxnmDr9zk/J19vYcHPOPoz/APEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzyO91r/VvUIKNtu3/ALb/AHf6/Lz34g6JJ4r8VaRrCa1qVquiXqXFlE/hS8kYufJJMjDaDzGMAKvHHOc11Ova9G+iRR3E2syXK6jp7SyLolzCjss8BZgGiO08Ham4k/KPmJ57GR/9f/pF5/r4zzB1+5yfk6+3sODnnH8Wv/xK/wDj4vP+Qrp55g6/6Tb8n5Ovt7Dg55J35Xr/AF94qUIqadu3/tv93+vyWTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzySeJLP8Af8+IP9fH10W55+5yf3HX0HsODnnXkf8A1/8ApF5/r4zzB1+5yfk6+3sODnkkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OebV+/9aeYoqOmnb/23+6cnpXiC0TUfEjM2ukSapC4xo9wTj7PbDLAQ/K3HAOCRg4IIzqyeJLP9/z4g/18fXRbnn7nJ/cdfQew4OeU0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeYhe2/8AV/UpqN1p2/8Abf7v9flyfijxBaS6cVVtdz/alg/z6PcKCBcQEnJhHzccDqTgAEnnVk8SWf7/AJ8Qf6+Protzz9zk/uOvoPYcHPKeLX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzyK/Nv2/rcEo8q0/r3f7v9flkSeJLP8Af8+IP9fH10W55+5yf3HX0HsODnnK0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ6yR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OecfRn/4mfij/AEi8/wCQrD1g6/6Na8n5Ovt7Dg55He61/q3qEFG23b/23+7/AF+SyeJLP9/z4g/18fXRbnn7nJ/cdfQew4OecrxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTz1kj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPOP4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzyTvyvX+vvCko80dO3/tv93+vyWTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzySeJLP8Af8+IP9fH10W55+5yf3HX0HsODnnXkf8A1/8ApF5/r4zzB1+5yfk6+3sODnkkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OebV+/9aeZMVHTTt/7b/dPGvGug2vi3XZdStdW17TdU0nW47m0n/sCe4UZtrQEvH5YwwaNCAx5A+6dwNaOleH7LTPiXfeMP7c8V3U9zDHazxz+H5Q0pzFgsy26qAAiYUICSoO4glT3mjP/AMTPxR/pF5/yFYesHX/RrXk/J19vYcHPOxI/+v8A9IvP9fGeYOv3OT8nX29hwc8zBu39d/UTpQclJp30/KP904T4j3emeIfCWo6Rdtr/ANmvby0hlP8AZE6HYZoQxBaDAcDO0dyFwCTgz+Cv7J8I+ErLQrFtfMNm0al/7EuwJHJVnkwYiVJYswXPGQOR13PFr/8AEr/4+Lz/AJCunnmDr/pNvyfk6+3sODnnYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4OeRN82/b+tylGNk7f17v93+vy8l+IOiSeK/FWkawmtalarol6lxZRP4UvJGLnySTIw2g8xjACrxxznNYHjDwTp/jHXb3Wm1fXtP8S2l/bp/aFtod2VZVtoORGFBicSFmX5t2CPvZVq95kf8A1/8ApF5/r4zzB1+5yfk6+3sODnnH0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OeU73X9dPUmNKDTvF62/9t/u/1+VLSNda20pYdXvtav79JYxLcx+HbmBZiCmGKeU21sY4BwSMgAHFQeKPEFpLpxVW13P9qWD/AD6PcKCBcQEnJhHzccDqTgAEnnrJH/1/+kXn+vjPMHX7nJ+Tr7ew4Oecfxa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnknflev8AX3l0ox5o6dv/AG3+7/X5LJ4ks/3/AD4g/wBfH10W55+5yf3HX0HsODnkk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc868j/AOv/ANIvP9fGeYOv3OT8nX29hwc8kj/6/wD0i8/18Z5g6/c5Pydfb2HBzzav3/rTzJio6adv/bf7pyeleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjOrJ4ks/3/AD4g/wBfH10W55+5yf3HX0HsODnlNGf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeYhe2/wDV/UpqN1p2/wDbf7v9flyfijxBaS6cVVtdz/alg/z6PcKCBcQEnJhHzccDqTgAEnnVk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc8p4tf/iV/8fF5/wAhXTzzB1/0m35Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc8ivzb9v63BKPKtP693+7/X5ZEniSz/f8+IP9fH10W55+5yf3HX0HsODnnK0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ6yR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x9Gf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnkd7rX+reoQUbbdv/bf7v9fksniSz/f8+IP9fH10W55+5yf3HX0HsODnnK8UeILSXTiqtruf7UsH+fR7hQQLiAk5MI+bjgdScAAk89ZI/wDr/wDSLz/XxnmDr9zk/J19vYcHPOP4tf8A4lf/AB8Xn/IV088wdf8ASbfk/J19vYcHPJO/K9f6+8KSjzR07f8Atv8Ad/r8lk8SWf7/AJ8Qf6+Protzz9zk/uOvoPYcHPPI6Ro/h3SPH2v+KrRNeW81LyYig0O5QIdytK3EIBLkRtyM7lJyd+K9Fkf/AF/+kXn+vjPMHX7nJ+Tr7ew4OeSR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OebV+/wDWnmQoxdvd7fp/d/r8vOvCvjm3vPFvjSxktNft1gvrSdWk02VpHDxRplo0iJj4hDLuwWDD5QQQeuk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc88n4GsNaj+IXjjV9VSCCK/nsYXW2lkmZJIYoyPvW6AgrLnPykFcbWBzXocj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPKj5P8Ar7xU07LnWv8Aw1vs9v67cn4o8QWkunFVbXc/2pYP8+j3CggXEBJyYR83HA6k4ABJ51ZPEln+/wCfEH+vj66Lc8/c5P7jr6D2HBzyni1/+JX/AMfF5/yFdPPMHX/Sbfk/J19vYcHPOxI/+v8A9IvP9fGeYOv3OT8nX29hwc8yr82/b+tzRKPKtP693+7/AF+WRJ4ks/3/AD4g/wBfH10W55+5yf3HX0HsODnnK0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ6yR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55He61/q3qEFG23b/ANt/u/1+SyeJLP8Af8+IP9fH10W55+5yf3HX0HsODnnK8UeILSXTiqtruf7UsH+fR7hQQLiAk5MI+bjgdScAAk89ZI/+v/0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf/Hxef8AIV088wdf9Jt+T8nX29hwc8k78r1/r7wpKPNHTt/7b/d/r8lk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc8kniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OedeR/8AX/6Ref6+M8wdfucn5Ovt7Dg55JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55tX7/ANaeZMVHTTt/7b/dOT0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ1ZPEln+/58Qf6+Protzz9zk/uOvoPYcHPKaM//Ez8Uf6Ref8AIVh6wdf9GteT8nX29hwc87Ej/wCv/wBIvP8AXxnmDr9zk/J19vYcHPMQvbf+r+pTUbrTt/7b/d/r8uT8UeILSXTiqtruf7UsH+fR7hQQLiAk5MI+bjgdScAAk86sniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OeU8Wv8A8Sv/AI+Lz/kK6eeYOv8ApNvyfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeRX5t+39bglHlWn9e7/d/r8vO/iNo/hzx1aW0GsJr5+x6hFOrjRLkMyHYJIywhDKHXjAI5VDg4wc7WPir4e8M6v4htbi+vTqVxqUMsdtcWzW+xPs0AEspeMFFDIeArPjBCMDz6rI/+v8A9IvP9fGeYOv3OT8nX29hwc8+Y6l4a1DUfEHxE/s+cPba+9vpl3Jcq6PbKtrGBIqrERIcTn5C0f3B8x3/ACt7q7/r7zNRtrGPa/pp/d/r8uyg8TQtalrtNbjuDJEZUj0i6dFbCZwxt1JwemQucDjnFZ/ijxBaS6cVVtdz/alg/wA+j3CggXEBJyYR83HA6k4ABJ53tG0+DRdEtdLs7i/NtYi3tojJDliiLGoLHYPmwB6ZwOOeavi1/wDiV/8AHxef8hXTzzB1/wBJt+T8nX29hwc8qd+V6/195pSUeaOnb/23+6LJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55JPEln+/58Qf6+Protzz9zk/uOvoPYcHPOvI/+v/0i8/18Z5g6/c5Pydfb2HBzySP/AK//AEi8/wBfGeYOv3OT8nX29hwc82r9/wCtPMmKjpp2/wDbf7pyeleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjOrJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55TRn/4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OediR/8AX/6Ref6+M8wdfucn5Ovt7Dg55iF7b/1f1Kajdadv/bf7v9flyfijxBaS6cVVtdz/AGpYP8+j3CggXEBJyYR83HA6k4ABJ5K1PFr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg55KV3zb9v63MqkY8kfd/qy/uh4tf/iV/wDHxef8hXTzzB1/0m35Pydfb2HBzzsSP/r/APSLz/XxnmDr9zk/J19vYcHPPJ+KdPu004lvEmuyg6pYDD2tuBk3EADcW4+YdQOhIGQQcHVk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnlp+9939bmqguVf5f4f7v8AX5a8j/6//SLz/XxnmDr9zk/J19vYcHPOPoz/APEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzysmmXn7/AP4qjxB/r4zzaW3P3OT/AKP19vYcHPOVpWn3baj4kC+JNdUrqkIJFrb5c/Z7Y7mzb8MOgAwMKOCSSRvVf109QhBW+7p/h/u/1+XWSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzj+LX/AOJX/wAfF5/yFdPPMHX/AEm35Pydfb2HBzysmmXn7/8A4qjxB/r4zzaW3P3OT/o/X29hwc85XinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHBJv3X/X6hSguaPy6f4f7v9fl1kj/6/wD0i8/18Z5g6/c5Pydfb2HBzySP/r/9IvP9fGeYOv3OT8nX29hwc85EmmXn7/8A4qjxB/r4zzaW3P3OT/o/X29hwc8kmmXn7/8A4qjxB/r4zzaW3P3OT/o/X29hwc82n/X3eZMaa0+XT/D/AHf6/JNGf/iZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg552JH/wBf/pF5/r4zzB1+5yfk6+3sODnnk9K0+7bUfEgXxJrqldUhBItbfLn7PbHc2bfhh0AGBhRwSSTqyaZefv8A/iqPEH+vjPNpbc/c5P8Ao/X29hwc8xB6f139SnBXXy6f4f7v9fkni1/+JX/x8Xn/ACFdPPMHX/Sbfk/J19vYcHPOxI/+v/0i8/18Z5g6/c5Pydfb2HBzzyfinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHB1ZNMvP3/8AxVHiD/Xxnm0tufucn/R+vt7Dg55E/e+7+twUFyr/AC/w/wB3+vy15H/1/wDpF5/r4zzB1+5yfk6+3sODnnH0Z/8AiZ+KP9IvP+QrD1g6/wCjWvJ+Tr7ew4OeVk0y8/f/APFUeIP9fGebS25+5yf9H6+3sODnnK0rT7ttR8SBfEmuqV1SEEi1t8ufs9sdzZt+GHQAYGFHBJJI3qv66eoQgrfd0/w/3f6/LrJH/wBf/pF5/r4zzB1+5yfk6+3sODnnH8Wv/wASv/j4vP8AkK6eeYOv+k2/J+Tr7ew4OeVk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnnK8U6fdppxLeJNdlB1SwGHtbcDJuIAG4tx8w6gdCQMgg4JN+6/6/UKUFzR+XT/AA/3f6/LrJH/ANf/AKRef6+M8wdfucn5Ovt7Dg55JH/1/wDpF5/r4zzB1+5yfk6+3sODnnIk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnkk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnm0/wCvu8yY01p8un+H+7/X5Joz/wDEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzzsSP/r/APSLz/XxnmDr9zk/J19vYcHPPJ6Vp922o+JAviTXVK6pCCRa2+XP2e2O5s2/DDoAMDCjgkknVk0y8/f/APFUeIP9fGebS25+5yf9H6+3sODnmIPT+u/qU4K6+XT/AA/3f6/JPFr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg552JH/1/wDpF5/r4zzB1+5yfk6+3sODnnk/FOn3aacS3iTXZQdUsBh7W3AybiABuLcfMOoHQkDIIODqyaZefv8A/iqPEH+vjPNpbc/c5P8Ao/X29hwc8ifvfd/W4KC5V/l/h/u/1+WvI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzj6M//Ez8Uf6Ref8AIVh6wdf9GteT8nX29hwc8rJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPOVpWn3baj4kC+JNdUrqkIJFrb5c/Z7Y7mzb8MOgAwMKOCSSRvVf109QhBW+7p/h/u/1+XWSP/r/APSLz/XxnmDr9zk/J19vYcHPOP4tf/iV/wDHxef8hXTzzB1/0m35Pydfb2HBzysmmXn7/wD4qjxB/r4zzaW3P3OT/o/X29hwc85XinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHBJv3X/AF+oUoLmj8un+H+7/X5dZI/+v/0i8/18Z5g6/c5Pydfb2HBzySP/AK//AEi8/wBfGeYOv3OT8nX29hwc85EmmXn7/wD4qjxB/r4zzaW3P3OT/o/X29hwc8kmmXn7/wD4qjxB/r4zzaW3P3OT/o/X29hwc82n/X3eZMaa0+XT/D/d/r8k0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeeT0rT7ttR8SBfEmuqV1SEEi1t8ufs9sdzZt+GHQAYGFHBJJOrJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPMQen9d/UpwV18un+H+7/X5J4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzzsSP/AK//AEi8/wBfGeYOv3OT8nX29hwc88n4p0+7TTiW8Sa7KDqlgMPa24GTcQANxbj5h1A6EgZBBwdWTTLz9/8A8VR4g/18Z5tLbn7nJ/0fr7ew4OeRP3vu/rcFBcq/y/w/3f6/LXkf/X/6Ref6+M8wdfucn5Ovt7Dg55x9Gf8A4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OeVk0y8/f8A/FUeIP8AXxnm0tufucn/AEfr7ew4OecrStPu21HxIF8Sa6pXVIQSLW3y5+z2x3Nm34YdABgYUcEkkjeq/rp6hCCt93T/AA/3f6/LrJH/ANf/AKRef6+M8wdfucn5Ovt7Dg55x/Fr/wDEr/4+Lz/kK6eeYOv+k2/J+Tr7ew4OeVk0y8/f/wDFUeIP9fGebS25+5yf9H6+3sODnnK8U6fdppxLeJNdlB1SwGHtbcDJuIAG4tx8w6gdCQMgg4JN+6/6/UKUFzR+XT/D/d/r8uskf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeSR/9f/pF5/r4zzB1+5yfk6+3sODnnIk0y8/f/wDFUeIP9fGebS25+5yf9H6+3sODnkk0y8/f/wDFUeIP9fGebS25+5yf9H6+3sODnm0/6+7zJjTWny6f4f7v9fkmjP8A8TPxR/pF5/yFYesHX/RrXk/J19vYcHPOxI/+v/0i8/18Z5g6/c5Pydfb2HBzzyelafdtqPiQL4k11SuqQgkWtvlz9ntjubNvww6ADAwo4JJJ1ZNMvP3/APxVHiD/AF8Z5tLbn7nJ/wBH6+3sODnmIPT+u/qU4K6+XT/D/d/r8k8Wv/xK/wDj4vP+Qrp55g6/6Tb8n5Ovt7Dg552JH/1/+kXn+vjPMHX7nJ+Tr7ew4OeeT8U6fdppxLeJNdlB1SwGHtbcDJuIAG4tx8w6gdCQMgg4OrJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPIn733f1uCguVf5f4f7v9flryP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzj6M//ABM/FH+kXn/IVh6wdf8ARrXk/J19vYcHPKyaZefv/wDiqPEH+vjPNpbc/c5P+j9fb2HBzzlaVp922o+JAviTXVK6pCCRa2+XP2e2O5s2/DDoAMDCjgkkkb1X9dPUIQVvu6f4f7v9fl1kj/6//SLz/XxnmDr9zk/J19vYcHPOP4tf/iV/8fF5/wAhXTzzB1/0m35Pydfb2HBzysmmXn7/AP4qjxB/r4zzaW3P3OT/AKP19vYcHPOV4p0+7TTiW8Sa7KDqlgMPa24GTcQANxbj5h1A6EgZBBwSb91/1+oUoLmj8un+H+7/AF+XWSP/AK//AEi8/wBfGeYOv3OT8nX29hwc8kj/AOv/ANIvP9fGeYOv3OT8nX29hwc85EmmXn7/AP4qjxB/r4zzaW3P3OT/AKP19vYcHPJJpl5+/wD+Ko8Qf6+M82ltz9zk/wCj9fb2HBzzaf8AX3eZMaa0+XT/AA/3f6/JNGf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeeT0rT7ttR8SBfEmuqV1SEEi1t8ufs9sdzZt+GHQAYGFHBJJOrJpl5+//AOKo8Qf6+M82ltz9zk/6P19vYcHPMQen9d/UpwV18un+H+7/AF+SeLX/AOJX/wAfF5/yFdPPMHX/AEm35Pydfb2HBzzsSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzyfinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHB1ZNMvP3/APxVHiD/AF8Z5tLbn7nJ/wBH6+3sODnkT977v63BQXKv8v8AD/d/r8teR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55rSL/wATOfTf+Ez1f+0cx3P2Uw2nmmLci+YU+z5xu4BxjOBznmppWn3baj4kC+JNdUrqkIJFrb5c/Z7Y7mzb8MOgAwMKOCSSRvVf109QhBW+7p/h/u/1+XWSP/r/APSLz/XxnmDr9zk/J19vYcHPOP4tf/iV/wDHxef8hXTzzB1/0m35Pydfb2HBzysmmXn7/wD4qjxB/r4zzaW3P3OT/o/X29hwc85XinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHBJv3X/AF+oUoLmj8un+H+7/X5dZI/+v/0i8/18Z5g6/c5Pydfb2HBzySP/AK//AEi8/wBfGeYOv3OT8nX29hwc85EmmXn7/wD4qjxB/r4zzaW3P3OT/o/X29hwc8kmmXn7/wD4qjxB/r4zzaW3P3OT/o/X29hwc82n/X3eZMaa0+XT/D/d/r8k0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeeT0rT7ttR8SBfEmuqV1SEEi1t8ufs9sdzZt+GHQAYGFHBJJOrJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPMQen9d/UpwV18un+H+7/X5J4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzyVl+KdPu004lvEmuyg6pYDD2tuBk3EADcW4+YdQOhIGQQcEpX977v63MqlNckf8vJf3TU8Wv/AMSv/j4vP+Qrp55g6/6Tb8n5Ovt7Dg552JH/ANf/AKRef6+M8wdfucn5Ovt7Dg555PxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTzqyeJLP9/wA+IP8AXx9dFuefucn9x19B7Dg55akubft/W5qqcuVe7+H+H+7/AF+WvI/+v/0i8/18Z5g6/c5Pydfb2HBzzj6M/wDxM/FH+kXn/IVh6wdf9GteT8nX29hwc8rJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55ytK8QWiaj4kZm10iTVIXGNHuCcfZ7YZYCH5W44BwSMHBBGRyV1r/VvUIU5W+Ht0/w/wB3+vy6yR/9f/pF5/r4zzB1+5yfk6+3sODnnH8Wv/xK/wDj4vP+Qrp55g6/6Tb8n5Ovt7Dg55WTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzzleKPEFpLpxVW13P8Aalg/z6PcKCBcQEnJhHzccDqTgAEnknJcr1/r7wpU5c0fd7dP8P8Ad/r8uskf/X/6Ref6+M8wdfucn5Ovt7Dg55JH/wBf/pF5/r4zzB1+5yfk6+3sODnnIk8SWf7/AJ8Qf6+Protzz9zk/uOvoPYcHPJJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55tSXf+tPMmNKWnu9un+H+7/X5Joz/8TPxR/pF5/wAhWHrB1/0a15Pydfb2HBzzsSP/AK//AEi8/wBfGeYOv3OT8nX29hwc88npXiC0TUfEjM2ukSapC4xo9wTj7PbDLAQ/K3HAOCRg4IIzqyeJLP8Af8+IP9fH10W55+5yf3HX0HsODnmISVt/6v6lOnK693t0/wAP93+vyTxa/wDxK/8Aj4vP+Qrp55g6/wCk2/J+Tr7ew4OediR/9f8A6Ref6+M8wdfucn5Ovt7Dg555PxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTzqyeJLP8Af8+IP9fH10W55+5yf3HX0HsODnkUlzb9v63BU5cq938P8P8Ad/r8teR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x9Gf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnlZPEln+/wCfEH+vj66Lc8/c5P7jr6D2HBzzlaV4gtE1HxIzNrpEmqQuMaPcE4+z2wywEPytxwDgkYOCCMjkrrX+reoQpyt8Pbp/h/u/1+XWSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzj+LX/AOJX/wAfF5/yFdPPMHX/AEm35Pydfb2HBzysniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OecrxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTyTkuV6/wBfeFKnLmj7vbp/h/u/1+XWSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzySP/r/APSLz/XxnmDr9zk/J19vYcHPORJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55JPEln+/wCfEH+vj66Lc8/c5P7jr6D2HBzzaku/9aeZMaUtPd7dP8P93+vyTRn/AOJn4o/0i8/5CsPWDr/o1ryfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg555PSvEFomo+JGZtdIk1SFxjR7gnH2e2GWAh+VuOAcEjBwQRnVk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc8xCStv/AFf1KdOV17vbp/h/u/1+SeLX/wCJX/x8Xn/IV088wdf9Jt+T8nX29hwc87Ej/wCv/wBIvP8AXxnmDr9zk/J19vYcHPPJ+KPEFpLpxVW13P8Aalg/z6PcKCBcQEnJhHzccDqTgAEnnVk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc8ikubft/W4KnLlXu/h/h/u/1+WvI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzj6M//Ez8Uf6Ref8AIVh6wdf9GteT8nX29hwc8rJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55ytK8QWiaj4kZm10iTVIXGNHuCcfZ7YZYCH5W44BwSMHBBGRyV1r/VvUIU5W+Ht0/w/3f6/LrJH/wBf/pF5/r4zzB1+5yfk6+3sODnnH8Wv/wASv/j4vP8AkK6eeYOv+k2/J+Tr7ew4OeVk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc85XijxBaS6cVVtdz/alg/z6PcKCBcQEnJhHzccDqTgAEnknJcr1/r7wpU5c0fd7dP8P93+vy6yR/8AX/6Ref6+M8wdfucn5Ovt7Dg55JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55yJPEln+/58Qf6+Protzz9zk/uOvoPYcHPJJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55tSXf8ArTzJjSlp7vbp/h/u/wBfkmjP/wATPxR/pF5/yFYesHX/AEa15Pydfb2HBzzsSP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzyeleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjOrJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55iElbf+r+pTpyuvd7dP8P93+vyTxa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg555PxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTzqyeJLP9/z4g/18fXRbnn7nJ/cdfQew4OeRSXNv2/rcFTlyr3fw/w/3f6/LXkf/X/6Ref6+M8wdfucn5Ovt7Dg55x9Gf8A4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OeVk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc85WleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjI5K61/q3qEKcrfD26f4f7v9fl1kj/6/wD0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc8rJ4ks/wB/z4g/18fXRbnn7nJ/cdfQew4OecrxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTyTkuV6/194UqcuaPu9un+H+7/X5dZI/+v8A9IvP9fGeYOv3OT8nX29hwc8kj/6//SLz/XxnmDr9zk/J19vYcHPORJ4ks/3/AD4g/wBfH10W55+5yf3HX0HsODnmsnjPR7i91CzgvNYlu7WeEzwLpNwXi3BSpdRDlSQCRnGcdD3tSXf+tPMmNOWnu9un+H+7/X5WNGf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OefJPAfjOHUPiP8R5BPr7WK3tjHFD9glkKSRqYpGMaI3lkmIYyFJCgEZBA9Ek8SWf7/nxB/r4+ui3PP3OT+46+g9hwc8zFqOjf9feKCdRKSj+Hay/l8v66J4tf/iV/8fF5/wAhXTzzB1/0m35Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc88n4o8QWkunFVbXc/2pYP8APo9woIFxAScmEfNxwOpOAASedWTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzylJc2/b+ty1Tlyr3fw/w/3f6/LXkf8A1/8ApF5/r4zzB1+5yfk6+3sODnnH0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OeVk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc85WleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjI5K61/q3qEKcrfD26f4f7v8AX5dZI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzj+LX/wCJX/x8Xn/IV088wdf9Jt+T8nX29hwc8rJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55yvFHiC0l04qra7n+1LB/n0e4UEC4gJOTCPm44HUnAAJPJOS5Xr/X3hSpy5o+726f4f7v8AX5dZI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzySP8A6/8A0i8/18Z5g6/c5Pydfb2HBzzkSeJLP9/z4g/18fXRbnn7nJ/cdfQew4OeSTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzzaku/wDWnmTGlLT3e3T/AA/3f6/JNGf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeeT0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ1ZPEln+/58Qf6+Protzz9zk/uOvoPYcHPMQkrb/1f1KdOV17vbp/h/u/1+SeLX/4lf/Hxef8AIV088wdf9Jt+T8nX29hwc87Ej/6//SLz/XxnmDr9zk/J19vYcHPPJ+KPEFpLpxVW13P9qWD/AD6PcKCBcQEnJhHzccDqTgAEnnVk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc8ikubft/W4KnLlXu/h/h/u/wBfl53Yan9u/af1yH/SE+w6HFbeYUy0mZoJdxXaNuPMwBjnaPXFeh6M/wDxM/FH+kXn/IVh6wdf9GteT8nX29hwc8+J+DvEtnfftLeMdSi/tXyDaC2H+gu826KS2jYtGiEqMxkjKg/dBAJxXrGleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjLlLWN2ZYaMpRbt+HnH+6dZI/+v/0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf/Hxef8AIV088wdf9Jt+T8nX29hwc8rJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55yvFHiC0l04qra7n+1LB/n0e4UEC4gJOTCPm44HUnAAJPKnJcr1/r7zWlTlzR93t0/w/3f6/LrJH/1/wDpF5/r4zzB1+5yfk6+3sODnkkf/X/6Ref6+M8wdfucn5Ovt7Dg55yJPEln+/58Qf6+Protzz9zk/uOvoPYcHPJJ4ks/wB/z4g/18fXRbnn7nJ/cdfQew4OebUl3/rTzJjSlp7vbp/h/u/1+SaM/wDxM/FH+kXn/IVh6wdf9GteT8nX29hwc87Ej/6//SLz/XxnmDr9zk/J19vYcHPPJ6V4gtE1HxIzNrpEmqQuMaPcE4+z2wywEPytxwDgkYOCCM6sniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OeYhJW3/AKv6lOnK693t0/w/3f6/JPFr/wDEr/4+Lz/kK6eeYOv+k2/J+Tr7ew4OeSsvxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTyUuZc2/b+tzKpSlyR938PJf3TU8Wv/AMSv/j4vP+Qrp55g6/6Tb8n5Ovt7Dg552JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55x/Fr/wDEr/4+Lz/kK6eeYOv+k2/J+Tr7ew4OeeSf42/D0+bjxXMczIw/0CbkDblv9T2wfy/O18T+X9bjbjCMebT+o/3f6/L0WR/9f/pF5/r4zzB1+5yfk6+3sODnnH0Z/wDiZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55429+OXgCG1u5YvEt1currIkMdjIHl2hTgbowobjAyQOBmqfgD4hXd54v1HR/E+i6roGoatcx3dokuJlkZIIN8TERgrIsapJjHRsEA43jTuv6/UmnOD0Xl/7b/dOr8F+NrfxTf+KLFTdW93o2rG0kiC+ZvRXCpMT5YCljG+E5I285zzp+LX/wCJX/x8Xn/IV088wdf9Jt+T8nX29hwc8/Pfwe1O/wBM8daR4h1K9QWvjyW782KJjEkNzHcbgdpBDkkhUGd2ZSP9/wBX+InxJ8KaRdXOjalr9xBqdvqNjPLA1nISEWWCUsSIscICcA9hwT1J35WiaE0rOdlr5eVunb+u3osj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPNZNSs7i91Czg1KSW7tpoTPAqAvFuClS6hcqSASAcZx0PfzTWfjJp2ow3Fj8OxqfibXp2DwRxWbLDEQYlEk5ZVIXc3bj5QCVzmua1f4Wah4e0B/Ful3F1qXxHtNRXVJ5YoJFjumYgywqg2gLlyem5wCoUbwooSmt4q/9L+6ew6M/wDxM/FH+kXn/IVh6wdf9GteT8nX29hwc87Ej/6//SLz/XxnmDr9zk/J19vYcHPPlfhT4veCr7UNVL+JHs5NQvobmKO8h8rCi2gDb32bFZTG6/ewSoxuyM9Za/EPwnqGvxaLp3iZL3UruRZIYrZPNDhQCSXVCoYBG+UkHgcHIzMLpf139TTmg7NW6f8Atv8Ad/r8tDxa/wDxK/8Aj4vP+Qrp55g6/wCk2/J+Tr7ew4OediR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x/Fr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg552JH/1/wDpF5/r4zzB1+5yfk6+3sODnlJ+9939blqPurT8P8P93+vyJH/1/wDpF5/r4zzB1+5yfk6+3sODnnH0Z/8AiZ+KP9IvP+QrD1g6/wCjWvJ+Tr7ew4OediR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x9Gf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnkb1X9dPUKcdNu3T/D/d/r8tiR/9f/pF5/r4zzB1+5yfk6+3sODnnH8Wv/xK/wDj4vP+Qrp55g6/6Tb8n5Ovt7Dg552JH/1/+kXn+vjPMHX7nJ+Tr7ew4Oecfxa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnkm/df9fqFKPvR07dP8P93+vy2JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55JH/1/wDpF5/r4zzB1+5yfk6+3sODnnO8R67p/h7R7/VNZ1C7trC3niMsrWzMFBaNQSFjJzkjjHpxXByfG7wp58kgm15tFa7SH+2/7P8A9D8wIrlSdu/eAPu7OwOMc1a/r8PMy5oRaUtNv0/u/wBfl2ujP/xM/FH+kXn/ACFYesHX/RrXk/J19vYcHPOxI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzx/gHxRo3iebxLd6DrEt7A+pwyfJDhtvkQIGZSgZfmjcDIGdnGe/lfxM+Lep3sWlat4QsPEj+G7DVFu7zUGt2t4LxY2REQSqCNjHcCHXrs+XORUw2/r/MdScYJSfZflH+6exeNdUsraG0srjU3ivLzVbI28Eiqsk+y4tyxVSuSVHOB2xxzz0Uj/6//SLz/XxnmDr9zk/J19vYcHPPzn8X7k/EP4g2Fj4V8Q20i6VaR3tne2zFz9pmuoIMM8fKbf3bAhcjHQlhXc6L8VNXbSIjr/gbxzHqhdDcCz0jfDvG3lS2GGcAhSOMgZbqRfF939biU0kk1Zf/ALN/s9D1OR/9f/pF5/r4zzB1+5yfk6+3sODnnH0Z/wDiZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55zPCPj3TPFF5qVhH/bOmaxazRSTabqVosNyIz5eJCgB45Hf+7kfMN1DW/GemeErnX31C41Ge7vNZgitLG2tw9xdv9mtMhEKjJGR3A+6OSwBT3X9dPUum48rl0/4Mf7v9fl3Uj/6/wD0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc88Svjzx3eCebT/AIb6s1m9xmNrzUIbaUhWAUvE0eUY7QcZxyMbhyaHiLxf8QJbELc/Dy8gQ39nJuOr27fOs8RRCBH1Zgqg9BuBIPOSfwtf1+YUmrxdu3T0/unrsj/6/wD0i8/18Z5g6/c5Pydfb2HBzySP/r/9IvP9fGeYOv3OT8nX29hwc88L4f8AFHjW/wBaitta8EXmk6fLMDNeHUoJ/JIAK5RYwWJIUDGOo4PfupH/ANf/AKRef6+M8wdfucn5Ovt7Dg55tP8Ar7vMIrbT8P8AD/dMfRn/AOJn4o/0i8/5CsPWDr/o1ryfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg55x9Gf8A4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OediR/9f/pF5/r4zzB1+5yfk6+3sODnmIPT+u/qU46rTt0/w/3f6/LH8Wv/AMSv/j4vP+Qrp55g6/6Tb8n5Ovt7Dg552JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55x/Fr/wDEr/4+Lz/kK6eeYOv+k2/J+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeRP3vu/rcFH3Vp+H+H+7/X5Ej/6//SLz/XxnmDr9zk/J19vYcHPOPoz/APEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzzsSP/r/9IvP9fGeYOv3OT8nX29hwc84+jP8A8TPxR/pF5/yFYesHX/RrXk/J19vYcHPI3qv66eoU46bdun+H+7/X5bEj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPOP4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzzxt78WktLW7ubvwh8QoLaJ1llll0eNEjVQpLOS2BgDPp0z3rN8X/GPwne6NND4c1e71nWGvrSW00+K0lR7t0nhbaGMOATtIH0HB6FyTcWv6/Myp1aaaba6f8Atv8AdPXJH/1/+kXn+vjPMHX7nJ+Tr7ew4OefHvDOo3Mf7THjrT0urgWdxZWlxIphG5njW2VCflyMCV8AYByM54ro/D3xW0DUIbqHX7258MaxBLCbjTtYCQSKSqNuUso3DrjgEgAlRuGfEz41tV+Pc/jq2ur1fDFw88H2glY3uxb2iFkCEgHLeUVVgMkpkAggUjKUo3g13/y8v6/LU/Z/1ltU+NHi29tZ72LTtVSa/WIgZfN4hRnRcruUO/0JIHB5+lpH/wBf/pF5/r4zzB1+5yfk6+3sODnn5N+EC3HgLWvDev6xKbLTNUMmm3c0sJKW6MkN1A/mDKgvvQ4I4VGJ77frKR/9f/pF5/r4zzB1+5yfk6+3sODnlJ3NaUFFJej+/lfYx/Fr/wDEr/4+Lz/kK6eeYOv+k2/J+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4Oecfxa/8AxK/+Pi8/5CunnmDr/pNvyfk6+3sODnmHQfFdlr+qeILPTm1Zk0q+jtpbl7TbDLKNodUO3JZCuCCB1XG4HJlP3vu/rc0skop/l/h/u/1+W9I/+v8A9IvP9fGeYOv3OT8nX29hwc84+jP/AMTPxR/pF5/yFYesHX/RrXk/J19vYcHPOxI/+v8A9IvP9fGeYOv3OT8nX29hwc84+jP/AMTPxR/pF5/yFYesHX/RrXk/J19vYcHPI3qv66eo6cdNu3T/AA/3f6/LYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4Oecfxa//ABK/+Pi8/wCQrp55g6/6Tb8n5Ovt7Dg552JH/wBf/pF5/r4zzB1+5yfk6+3sODnnH8Wv/wASv/j4vP8AkK6eeYOv+k2/J+Tr7ew4OeSb91/1+oUo+9HTt0/w/wB3+vy2JH/1/wDpF5/r4zzB1+5yfk6+3sODnkkf/X/6Ref6+M8wdfucn5Ovt7Dg55JH/wBf/pF5/r4zzB1+5yfk6+3sODnnlPiBceNIbfzfAx0+5ZHZ7iHUoZA8rBYzGI9qhQxIYfMQPu+pq0/6+7zJUbW0/D/D/d/r8tPRn/4mfij/AEi8/wCQrD1g6/6Na8n5Ovt7Dg552JH/ANf/AKRef6+M8wdfucn5Ovt7Dg558f07x74u07VNXl1b4f66LSfUozcnT54ryWCQW8O1fLWMbshEOcqBvA5PB1j8aPDNtdXNt4jPiLw5db4pkh1bTSjyoSBuARWPGw9cA8YzzUw2/r/MUpwTV9Nv/bf7p2Xi1/8AiV/8fF5/yFdPPMHX/Sbfk/J19vYcHPOxI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzz5T4i+MngO8sTHb+KZpH/ALRs58fYZRlI54XduYuoVGOO+3oe+x4e+LnhPWoLprrV7nRJ1lhkFtrCxW0kkbKjrKvVSCvIwegBxhgSK6lf0/rcUZ02kk1/XL/d/r8vKPgdcpe/HnxbqdtJcNY6hHdXVrceSR58TX8eHAK9OD2HIx14r33Rn/4mfij/AEi8/wCQrD1g6/6Na8n5Ovt7Dg55+ffgBMtj4o8KPdGeCPUNBuLS1kWIss0yag8roDtIyqDcf+A/3gD7outabo134muNY1j7BbvrEKLLd7YVZvslscZZQN2FJA9F6GiWjQsNG0H/AF1j5M6aR/8AX/6Ref6+M8wdfucn5Ovt7Dg55818X/Evw43iW08J2up3l3q0+sWkb+VCvlwNHPAxEjED5vlZQFDfMuGA7wfEb4h2t7pseg+A9dg1PxBrt2tnA1tMW+zIVG64YxKWUpjjBBH3gCFIOb4+8CWvh34IvpPh5b1tU0u7tbq0ltoZI5Jb3dGhmGAW8xt7BV3HGVA6KaHqtRJtNci1Vunpptv/AF6exyP/AK//AEi8/wBfGeYOv3OT8nX29hwc8kj/AOv/ANIvP9fGeYOv3OT8nX29hwc88r4I8eaL4x0q3n0/V1OoTpFczWCMrywEeWr7hsB+V/lBwAcKQDuGeqkf/X/6Ref6+M8wdfucn5Ovt7Dg55r+vy8y4JOzS7dP8P8Ad/r8sfRn/wCJn4o/0i8/5CsPWDr/AKNa8n5Ovt7Dg552JH/1/wDpF5/r4zzB1+5yfk6+3sODnnH0Z/8AiZ+KP9IvP+QrD1g6/wCjWvJ+Tr7ew4OediR/9f8A6Ref6+M8wdfucn5Ovt7Dg55iD0/rv6luOq07dP8AD/d/r8sfxa//ABK/+Pi8/wCQrp55g6/6Tb8n5Ovt7Dg55KPFr/8AEr/4+Lz/AJCunnmDr/pNvyfk6+3sODnkpN+9939bmVSPuR0/Dyj/AHTL8U6fdppxLeJNdlB1SwGHtbcDJuIAG4tx8w6gdCQMgg4OrJpl5+//AOKo8Qf6+M82ltz9zk/6P19vYcHPKeLX/wCJX/x8Xn/IV088wdf9Jt+T8nX29hwc87Ej/wCv/wBIvP8AXxnmDr9zk/J19vYcHPIvi+7+tzdX5Vp+H+H+7/X5ZEmmXn7/AP4qjxB/r4zzaW3P3OT/AKP19vYcHPPEa78PNK8az67b+ItT1q5FtqsZikFvCkgLWtsGbcIAQcEDaMKdiEqSMn06R/8AX/6Ref6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55Huv66eooq6aa7dP8P8Ad/r8vMvH3gT/AIRX4Uyp4Y1bW5G8NXcerafDcxwbI5EYO0jkwgnarykKTzgcHgGj8MdFv2+Hj+ItR1HUbXVPEGuWt9cJFYRIG33kWxyzRMx6mRBkL84wpBO726+igvLW8trtrie3mkWOWKW2DJIpCAhgUweOMHrxwc84/iOKC00KG2tGuILeHUtNjiijtgiIq3NuAAAmFwBgAY6Dj1c/hf8AX6mdKlapGVu3T0/uk0mmXn7/AP4qjxB/r4zzaW3P3OT/AKP19vYcHPJJpl5+/wD+Ko8Qf6+M82ltz9zk/wCj9fb2HBzzryP/AK//AEi8/wBfGeYOv3OT8nX29hwc8kj/AOv/ANIvP9fGeYOv3OT8nX29hwc80l/X3eZcb6adun+H+7/X5cK3hiDXLjxFa6vqeo3sEerQtsudOtZVZ/s1uN5D25AYKxUYA4A4OSToaT4Ns9DF2NE1K/04TTReZ9k0yzh3hduN222HI3Nge/TnnS0Z/wDiZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg552JH/1/+kXn+vjPMHX7nJ+Tr7ew4OeYgtP67+pT3Wnbp/h/u/1+XJ+KdPu004lvEmuyg6pYDD2tuBk3EADcW4+YdQOhIGQQcHVk0y8/f/8AFUeIP9fGebS25+5yf9H6+3sODnlPFr/8Sv8A4+Lz/kK6eeYOv+k2/J+Tr7ew4OediR/9f/pF5/r4zzB1+5yfk6+3sODnkXxfd/W4K/KtPw/w/wB3+vyyJNMvP3//ABVHiD/Xxnm0tufucn/R+vt7Dg55ytK0+7bUfEgXxJrqldUhBItbfLn7PbHc2bfhh0AGBhRwSST1kj/6/wD0i8/18Z5g6/c5Pydfb2HBzzj6M/8AxM/FH+kXn/IVh6wdf9GteT8nX29hwc8j3X9dPUIXtt26f4f7v9fksmmXn7//AIqjxB/r4zzaW3P3OT/o/X29hwc85XinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHB6yR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4Oecfxa/8AxK/+Pi8/5CunnmDr/pNvyfk6+3sODnkn8L/r9QpX5o6dun+H+7/X5LJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPJJpl5+//wCKo8Qf6+M82ltz9zk/6P19vYcHPOvI/wDr/wDSLz/XxnmDr9zk/J19vYcHPJI/+v8A9IvP9fGeYOv3OT8nX29hwc82l/X3eZMb6adun+H+7/X5eRT/AAn0TXPEXim9m1fxHa3Ul2tncSWQS2+1RSRQSOJVSEKSWdiRgbsAkE8m3498FWmm/B3xHo9nq2sLpVlaGWK0NvAkbGJVkXewgDZLKCTuBbqSScnutGf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeZhqv67+onTXbdLp5R/u/l/w3gvwc0WOL4N6VqFtf3tpcXmp2yzC2tICH236qjM5hLsVySoZiM8YwcH2OTTLz9/8A8VR4g/18Z5tLbn7nJ/0fr7ew4OeeY0XwyPBfw407QF1G6uxaarZnzhZmIPuvonztIYgjdjGecDjnFd9I/wDr/wDSLz/XxnmDr9zk/J19vYcHPIvjfy/rcdNNQjp+H+H+6edeOPh5LrN0uuab4h1WLxbpsi/2dez20SqD8vyS+XApZD8w2nONx+U7iG5j4Y+Dtc1TxFq/i/x1f3tn4uiuIrIJb2kDeSojiO/JjdQxRlA24OMgk7yB7ZI/+v8A9IvP9fGeYOv3OT8nX29hwc84+jP/AMTPxR/pF5/yFYesHX/RrXk/J19vYcHPI91/X6ijC75rdv8A23+7/Xy0WTTLz9//AMVR4g/18Z5tLbn7nJ/0fr7ew4OecrxTp92mnEt4k12UHVLAYe1twMm4gAbi3HzDqB0JAyCDg9ZI/wDr/wDSLz/XxnmDr9zk/J19vYcHPOP4tf8A4lf/AB8Xn/IV088wdf8ASbfk/J19vYcHPKn8L/r9S6V+aOnbp/h/u/1+SyaZefv/APiqPEH+vjPNpbc/c5P+j9fb2HBzySaZefv/APiqPEH+vjPNpbc/c5P+j9fb2HBzzryP/r/9IvP9fGeYOv3OT8nX29hwc8kj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPNpf193mTG+mnbp/h/u/wBflyelafdtqPiQL4k11SuqQgkWtvlz9ntjubNvww6ADAwo4JJJ1ZNMvP3/APxVHiD/AF8Z5tLbn7nJ/wBH6+3sODnlNGf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeYht/Xf1Kd7rTt0/w/wB3+vy5PxTp92mnEt4k12UHVLAYe1twMm4gAbi3HzDqB0JAyCDg6smmXn7/AP4qjxB/r4zzaW3P3OT/AKP19vYcHPKeLX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzyL4vu/rcFflWn4f4f7v9flkSaZefv8A/iqPEH+vjPNpbc/c5P8Ao/X29hwc85WlafdtqPiQL4k11SuqQgkWtvlz9ntjubNvww6ADAwo4JJJ6yR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x9Gf/AImfij/SLz/kKw9YOv8Ao1ryfk6+3sODnke6/rp6hC9tu3T/AA/3f6/JZNMvP3//ABVHiD/Xxnm0tufucn/R+vt7Dg55yvFOn3aacS3iTXZQdUsBh7W3AybiABuLcfMOoHQkDIIOD1kj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPOP4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzyT+F/1+oUr80dO3T/AA/3f6/LI1rwLpmtXcl1rF5d6hcrJHGs13pNlK4T5eMtakjqcL79DnnzX9pbQ7iy+GcCWl7ql3Y2epQDyHs4Y4beMQMit+7hTYASqAZA+YcciveZH/1/+kXn+vjPMHX7nJ+Tr7ew4OecXxr4fs/FvhvU9D1O61JLO8mhEhhiCuQrRt1MZAOVHGPw5q1/X9XMZxcoNJdO3p/dOA8LeBk1bwXc6D4nu9SxBJZwTWhtbeQRyCxtUYq5hYq6hmRWVgcAHJJJbO1H4H6X4fs7rV/Al/r1t4n09hLpzOVZXkABCMCij5sleSByMgjIPqWjP/xM/FH+kXn/ACFYesHX/RrXk/J19vYcHPOxI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzMNr/ANfmaSgpWTXRdPKP908I1rxzcX3wJfxZF4ovzqpntlFtNDaiP7bHJEWACxZ4KGRVLZKKpIwTXeeAPAr+EfCNtpNrruq2siSRSXK21tA0bTkIZGDPb7jzkLuOdoUVl+KPhvocPihvFcF3rMV4+t6dctaxqEtnlE0SeY0YjGX/AHkjZJyS5PO459Pkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeWrXt/X5kU1O6lJfh/h1+H0MiTTLz9/8A8VR4g/18Z5tLbn7nJ/0fr7ew4OecrStPu21HxIF8Sa6pXVIQSLW3y5+z2x3Nm34YdABgYUcEkk9ZI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzzj6M//Ez8Uf6Ref8AIVh6wdf9GteT8nX29hwc8y91/XT1NYXtt26f4f7v9fksmmXn7/8A4qjxB/r4zzaW3P3OT/o/X29hwc85XinT7tNOJbxJrsoOqWAw9rbgZNxAA3FuPmHUDoSBkEHB6yR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x/Fr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg55J/C/6/UKV+aOnbp/h/u/1+SyaZefv/wDiqPEH+vjPNpbc/c5P+j9fb2HBzySaZefv/wDiqPEH+vjPNpbc/c5P+j9fb2HBzzryP/r/APSLz/XxnmDr9zk/J19vYcHPJI/+v/0i8/18Z5g6/c5Pydfb2HBzzaX9fd5kxvpp26f4f7v9flyelafdtqPiQL4k11SuqQgkWtvlz9ntjubNvww6ADAwo4JJJ1ZNMvP3/wDxVHiD/Xxnm0tufucn/R+vt7Dg55TRn/4mfij/AEi8/wCQrD1g6/6Na8n5Ovt7Dg552JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55iG39d/Up3utO3T/D/d/r8uT8U6fdppxLeJNdlB1SwGHtbcDJuIAG4tx8w6gdCQMgg4OF8Tvh3B4m8O648l1qGpa0Idlm81jaLIzqAyJ5v2dWQFuMBlyCfU57Hxa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg55F8X3f1uK3NBJr8P8P93+vy+efHFtqHgXSvhn4g1W+1PZo5SxurdUhE1q8lrGCISYtjbRE4w5OdqYPJan/C34fW/jS2uvF/jifUZvEc98snzRRzwtDJFE6ZR43Q/JINqnoNoAGBXuPibR9O8R6LqGk6yLy50+6miEsRjZN4BjYZKqCCCBgAjOBwc8w6M/8AxM/FH+kXn/IVh6wdf9GteT8nX29hwc8tvVf1+pnCm27taadP8K/l7GRpfgXTdFubi40a8u9PuDIkZltdJsoWKZQkErag9QDt7kDg93+KdPu004lvEmuyg6pYDD2tuBk3EADcW4+YdQOhIGQQcHrJH/1/+kXn+vjPMHX7nJ+Tr7ew4Oecfxa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnlTXuv+v1NaXxR07dP8P93+vy4zxN8HPC/iO6lutVn1R7n7QWaWG1gt2kMmwu0hjgUsxOT82eTkfeOcdv2efAw8zE3iD5ZVUZfsduc/u+vJx+FexyP/r/APSLz/XxnmDr9zk/J19vYcHPJI/+v/0i8/18Z5g6/c5Pydfb2HBzzVl/X/DkKK0vFdOi8v7p454b+D+i6fe6/FoviHxjpMcN9Db4sbow+avlRSAyYj5YGV8dO2Bzk93o3hafRrO4trfxf4uuEa6STde+VcvnEY+/JASOnC5x7c86GjP/AMTPxR/pF5/yFYesHX/RrXk/J19vYcHPOxI/+v8A9IvP9fGeYOv3OT8nX29hwc8qDuv6/wAxKkoyUku3T/D/AHTk/FOn3aacS3iTXZQdUsBh7W3AybiABuLcfMOoHQkDIIOCVqeLX/4lf/Hxef8AIV088wdf9Jt+T8nX29hwc8lT9r7v63FUvyR0/DyX90y/FHiC0l04qra7n+1LB/n0e4UEC4gJOTCPm44HUnAAJPOrJ4ks/wB/z4g/18fXRbnn7nJ/cdfQew4OeU8Wv/xK/wDj4vP+Qrp55g6/6Tb8n5Ovt7Dg552JH/1/+kXn+vjPMHX7nJ+Tr7ew4OeWr82/b+tzVKPKtP693+7/AF+WRJ4ks/3/AD4g/wBfH10W55+5yf3HX0HsODnnK0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ6yR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55He61/q3qEFG23b/ANt/u/1+SyeJLP8Af8+IP9fH10W55+5yf3HX0HsODnnK8UeILSXTiqtruf7UsH+fR7hQQLiAk5MI+bjgdScAAk89ZI/+v/0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf/Hxef8AIV088wdf9Jt+T8nX29hwc8k78r1/r7wpKPNHTt/7b/d/r8lk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc8kniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OedeR/8AX/6Ref6+M8wdfucn5Ovt7Dg55JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55tX7/ANaeZMVHTTt/7b/dOT0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ1ZPEln+/58Qf6+Protzz9zk/uOvoPYcHPKaM//Ez8Uf6Ref8AIVh6wdf9GteT8nX29hwc87Ej/wCv/wBIvP8AXxnmDr9zk/J19vYcHPMQvbf+r+pTUbrTt/7b/d/r8uT8UeILSXTiqtruf7UsH+fR7hQQLiAk5MI+bjgdScAAk86sniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OeU8Wv8A8Sv/AI+Lz/kK6eeYOv8ApNvyfk6+3sODnnYkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeRX5t+39bglHlWn9e7/d/r8siTxJZ/v8AnxB/r4+ui3PP3OT+46+g9hwc85WleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjPWSP/AK//AEi8/wBfGeYOv3OT8nX29hwc84+jP/xM/FH+kXn/ACFYesHX/RrXk/J19vYcHPI73Wv9W9Qgo227f+2/3f6/JZPEln+/58Qf6+Protzz9zk/uOvoPYcHPOV4o8QWkunFVbXc/wBqWD/Po9woIFxAScmEfNxwOpOAASeeskf/AF/+kXn+vjPMHX7nJ+Tr7ew4Oecfxa//ABK/+Pi8/wCQrp55g6/6Tb8n5Ovt7Dg55J35Xr/X3hSUeaOnb/23+7/X5LJ4ks/3/PiD/Xx9dFuefucn9x19B7Dg55JPEln+/wCfEH+vj66Lc8/c5P7jr6D2HBzzryP/AK//AEi8/wBfGeYOv3OT8nX29hwc8kj/AOv/ANIvP9fGeYOv3OT8nX29hwc82r9/608yYqOmnb/23+6cnpXiC0TUfEjM2ukSapC4xo9wTj7PbDLAQ/K3HAOCRg4IIzqyeJLP9/z4g/18fXRbnn7nJ/cdfQew4OeU0Z/+Jn4o/wBIvP8AkKw9YOv+jWvJ+Tr7ew4OediR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeYhe2/8AV/UpqN1p2/8Abf7v9flyfijxBaS6cVVtdz/alg/z6PcKCBcQEnJhHzccDqTgAEnnVk8SWf7/AJ8Qf6+Protzz9zk/uOvoPYcHPKeLX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzyK/Nv2/rcEo8q0/r3f7v9flkSeJLP8Af8+IP9fH10W55+5yf3HX0HsODnnK0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ6yR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OecfRn/4mfij/AEi8/wCQrD1g6/6Na8n5Ovt7Dg55He61/q3qEFG23b/23+7/AF+SyeJLP9/z4g/18fXRbnn7nJ/cdfQew4OecrxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTz1kj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPOP4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzyTvyvX+vvCko80dO3/tv93+vyWTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzySeJLP8Af8+IP9fH10W55+5yf3HX0HsODnnXkf8A1/8ApF5/r4zzB1+5yfk6+3sODnkkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OebV+/9aeZMVHTTt/7b/dOT0rxBaJqPiRmbXSJNUhcY0e4Jx9nthlgIflbjgHBIwcEEZ1ZPEln+/58Qf6+Protzz9zk/uOvoPYcHPKaM//ABM/FH+kXn/IVh6wdf8ARrXk/J19vYcHPOxI/wDr/wDSLz/XxnmDr9zk/J19vYcHPMQvbf8Aq/qU1G607f8Atv8Ad/r8uT8UeILSXTiqtruf7UsH+fR7hQQLiAk5MI+bjgdScAAk86sniSz/AH/PiD/Xx9dFuefucn9x19B7Dg55Txa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg55Ffm37f1uCUeVaf17v93+vyyJPEln+/58Qf6+Protzz9zk/uOvoPYcHPOVpXiC0TUfEjM2ukSapC4xo9wTj7PbDLAQ/K3HAOCRg4IIz1kj/AOv/ANIvP9fGeYOv3OT8nX29hwc84+jP/wATPxR/pF5/yFYesHX/AEa15Pydfb2HBzyO91r/AFb1CCjbbt/7b/d/r8lk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc85XijxBaS6cVVtdz/alg/z6PcKCBcQEnJhHzccDqTgAEnnrJH/ANf/AKRef6+M8wdfucn5Ovt7Dg55x/Fr/wDEr/4+Lz/kK6eeYOv+k2/J+Tr7ew4OeSd+V6/194UlHmjp2/8Abf7v9fksniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OeSTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzzryP8A6/8A0i8/18Z5g6/c5Pydfb2HBzySP/r/APSLz/XxnmDr9zk/J19vYcHPNq/f+tPMmKjpp2/9t/unJ6V4gtE1HxIzNrpEmqQuMaPcE4+z2wywEPytxwDgkYOCCM6sniSz/f8APiD/AF8fXRbnn7nJ/cdfQew4OeU0Z/8AiZ+KP9IvP+QrD1g6/wCjWvJ+Tr7ew4OediR/9f8A6Ref6+M8wdfucn5Ovt7Dg55iF7b/ANX9Smo3Wnb/ANt/u/1+XJ+KPEFpLpxVW13P9qWD/Po9woIFxAScmEfNxwOpOAASedWTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzyni1/+JX/x8Xn/ACFdPPMHX/Sbfk/J19vYcHPOxI/+v/0i8/18Z5g6/c5Pydfb2HBzyK/Nv2/rcEo8q0/r3f7v9flkSeJLP9/z4g/18fXRbnn7nJ/cdfQew4OecrSvEFomo+JGZtdIk1SFxjR7gnH2e2GWAh+VuOAcEjBwQRnrJH/1/wDpF5/r4zzB1+5yfk6+3sODnnH0Z/8AiZ+KP9IvP+QrD1g6/wCjWvJ+Tr7ew4OeR3utf6t6hBRtt2/9t/u/1+SyeJLP9/z4g/18fXRbnn7nJ/cdfQew4OecrxR4gtJdOKq2u5/tSwf59HuFBAuICTkwj5uOB1JwACTz1kj/AOv/ANIvP9fGeYOv3OT8nX29hwc84/i1/wDiV/8AHxef8hXTzzB1/wBJt+T8nX29hwc8k78r1/r7wpKPNHTt/wC2/wB3+vyWTxJZ/v8AnxB/r4+ui3PP3OT+46+g9hwc8kniSz/f8+IP9fH10W55+5yf3HX0HsODnnXkf/X/AOkXn+vjPMHX7nJ+Tr7ew4OeSR/9f/pF5/r4zzB1+5yfk6+3sODnm1fv/WnmTFR007f+2/3Tk9K8QWiaj4kZm10iTVIXGNHuCcfZ7YZYCH5W44BwSMHBBGdWTxJZ/v8AnxB/r4+ui3PP3OT+46+g9hwc8poz/wDEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzzsSP/r/APSLz/XxnmDr9zk/J19vYcHPMQvbf+r+pTUbrTt/7b/d/r8uT8UeILSXTiqtruf7UsH+fR7hQQLiAk5MI+bjgdScAAk86sniSz/f8+IP9fH10W55+5yf3HX0HsODnlPFr/8AEr/4+Lz/AJCunnmDr/pNvyfk6+3sODnnYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4OeRX5t+39bglHlWn9e7/AHf6/LIk8SWf7/nxB/r4+ui3PP3OT+46+g9hwc85WleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjPWSP/r/APSLz/XxnmDr9zk/J19vYcHPOPoz/wDEz8Uf6Ref8hWHrB1/0a15Pydfb2HBzyO91r/VvUIKNtu3/tv93+vyWTxJZ/v+fEH+vj66Lc8/c5P7jr6D2HBzzleKPEFpLpxVW13P9qWD/Po9woIFxAScmEfNxwOpOAASeeskf/X/AOkXn+vjPMHX7nJ+Tr7ew4Oecfxa/wDxK/8Aj4vP+Qrp55g6/wCk2/J+Tr7ew4OeSd+V6/194UlHmjp2/wDbf7v9fksniSz/AH/PiD/Xx9dFuefucn9x19B7Dg55JPEln+/58Qf6+Protzz9zk/uOvoPYcHPOvI/+v8A9IvP9fGeYOv3OT8nX29hwc8kj/6//SLz/XxnmDr9zk/J19vYcHPNq/f+tPMmKjpp2/8Abf7pyeleILRNR8SMza6RJqkLjGj3BOPs9sMsBD8rccA4JGDggjOrJ4ks/wB/z4g/18fXRbnn7nJ/cdfQew4OeU0Z/wDiZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg552JH/1/+kXn+vjPMHX7nJ+Tr7ew4OeYhe2/9X9Smo3Wnb/23+7/AF+XJ+KPEFpLpxVW13P9qWD/AD6PcKCBcQEnJhHzccDqTgAEnkrU8Wv/AMSv/j4vP+Qrp55g6/6Tb8n5Ovt7Dg55KV3zb9v63MqkY8kfd/qy/uh4tf8A4lf/AB8Xn/IV088wdf8ASbfk/J19vYcHPOxI/wDr/wDSLz/XxnmDr9zk/J19vYcHPPNeKdGv49OYv4l1eUf2rYLh47TGTcW4DcQDkZBHbIGQRkHVk0PUP9I/4qrWuLmMf6qz5/1fP+o/ziqV+bbt/W5S5OVar+uX+7/X5aEj/wCv/wBIvP8AXxnmDr9zk/J19vYcHPOPoz/8TPxR/pF5/wAhWHrB1/0a15Pydfb2HBzzYk0PUP8ASP8Aiqta4uYx/qrPn/V8/wCo/wA4rK0rRb9tR8SgeJdXUpqsCsRHaZkP2e1O45g6jIHGBhRxnJI73Wn9W9Qp8lt10/8Abf7p0sj/AOv/ANIvP9fGeYOv3OT8nX29hwc84/i1/wDiV/8AHxef8hXTzzB1/wBJt+T8nX29hwc82JND1D/SP+Kq1ri5jH+qs+f9Xz/qP84rK8U6Nfx6cxfxLq8o/tWwXDx2mMm4twG4gHIyCO2QMgjIJO/K9P6+8KXJzR1XT/23+6dLI/8Ar/8ASLz/AF8Z5g6/c5Pydfb2HBzySP8A6/8A0i8/18Z5g6/c5Pydfb2HBzznyaHqH+kf8VVrXFzGP9VZ8/6vn/Uf5xRJoeof6R/xVWtcXMY/1Vnz/q+f9R/nFWr9v6+8mPJpqun/ALb/AHSvoz/8TPxR/pF5/wAhWHrB1/0a15Pydfb2HBzzsSP/AK//AEi8/wBfGeYOv3OT8nX29hwc881pWi37aj4lA8S6upTVYFYiO0zIfs9qdxzB1GQOMDCjjOSdWTQ9Q/0j/iqta4uYx/qrPn/V8/6j/OKiF7bf1f1K9y61XT/23+6V/Fr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg552JH/1/wDpF5/r4zzB1+5yfk6+3sODnnmvFOjX8enMX8S6vKP7VsFw8dpjJuLcBuIByMgjtkDIIyDqyaHqH+kf8VVrXFzGP9VZ8/6vn/Uf5xQr823b+twXJyrVf1y/3f6/LQkf/X/6Ref6+M8wdfucn5Ovt7Dg55x9Gf8A4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OebEmh6h/pH/FVa1xcxj/VWfP8Aq+f9R/nFZWlaLftqPiUDxLq6lNVgViI7TMh+z2p3HMHUZA4wMKOM5JHe60/q3qFPktuun/tv906WR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x/Fr/8AEr/4+Lz/AJCunnmDr/pNvyfk6+3sODnmxJoeof6R/wAVVrXFzGP9VZ8/6vn/AFH+cVleKdGv49OYv4l1eUf2rYLh47TGTcW4DcQDkZBHbIGQRkEnflen9feFLk5o6rp/7b/dOlkf/X/6Ref6+M8wdfucn5Ovt7Dg55JH/wBf/pF5/r4zzB1+5yfk6+3sODnnPk0PUP8ASP8Aiqta4uYx/qrPn/V8/wCo/wA4ok0PUP8ASP8Aiqta4uYx/qrPn/V8/wCo/wA4q1ft/X3kx5NNV0/9t/ulfRn/AOJn4o/0i8/5CsPWDr/o1ryfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg555rStFv21HxKB4l1dSmqwKxEdpmQ/Z7U7jmDqMgcYGFHGck6smh6h/pH/FVa1xcxj/VWfP+r5/1H+cVEL22/q/qV7l1qun/ALb/AHSv4tf/AIlf/Hxef8hXTzzB1/0m35Pydfb2HBzzsSP/AK//AEi8/wBfGeYOv3OT8nX29hwc8814p0a/j05i/iXV5R/atguHjtMZNxbgNxAORkEdsgZBGQdWTQ9Q/wBI/wCKq1ri5jH+qs+f9Xz/AKj/ADihX5tu39bguTlWq/rl/u/1+WhI/wDr/wDSLz/XxnmDr9zk/J19vYcHPOPoz/8AEz8Uf6Ref8hWHrB1/wBGteT8nX29hwc82JND1D/SP+Kq1ri5jH+qs+f9Xz/qP84rK0rRb9tR8SgeJdXUpqsCsRHaZkP2e1O45g6jIHGBhRxnJI73Wn9W9Qp8lt10/wDbf7p0sj/6/wD0i8/18Z5g6/c5Pydfb2HBzzj+LX/4lf8Ax8Xn/IV088wdf9Jt+T8nX29hwc82JND1D/SP+Kq1ri5jH+qs+f8AV8/6j/OKyvFOjX8enMX8S6vKP7VsFw8dpjJuLcBuIByMgjtkDIIyCTvyvT+vvClyc0dV0/8Abf7p0sj/AOv/ANIvP9fGeYOv3OT8nX29hwc8kj/6/wD0i8/18Z5g6/c5Pydfb2HBzznyaHqH+kf8VVrXFzGP9VZ8/wCr5/1H+cUSaHqH+kf8VVrXFzGP9VZ8/wCr5/1H+cVav2/r7yY8mmq6f+2/3Svoz/8AEz8Uf6Ref8hWHrB1/wBGteT8nX29hwc87Ej/AOv/ANIvP9fGeYOv3OT8nX29hwc881pWi37aj4lA8S6upTVYFYiO0zIfs9qdxzB1GQOMDCjjOSdWTQ9Q/wBI/wCKq1ri5jH+qs+f9Xz/AKj/ADiohe239X9SvcutV0/9t/ulfxa//Er/AOPi8/5CunnmDr/pNvyfk6+3sODnnYkf/X/6Ref6+M8wdfucn5Ovt7Dg555rxTo1/HpzF/Euryj+1bBcPHaYybi3AbiAcjII7ZAyCMg6smh6h/pH/FVa1xcxj/VWfP8Aq+f9R/nFCvzbdv63BcnKtV/XL/d/r8tCR/8AX/6Ref6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP9IvP+QrD1g6/6Na8n5Ovt7Dg55sSaHqH+kf8AFVa1xcxj/VWfP+r5/wBR/nFZWlaLftqPiUDxLq6lNVgViI7TMh+z2p3HMHUZA4wMKOM5JHe60/q3qFPktuun/tv906WR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4Oecfxa/8AxK/+Pi8/5CunnmDr/pNvyfk6+3sODnmxJoeof6R/xVWtcXMY/wBVZ8/6vn/Uf5xWV4p0a/j05i/iXV5R/atguHjtMZNxbgNxAORkEdsgZBGQSd+V6f194UuTmjqun/tv906WR/8AX/6Ref6+M8wdfucn5Ovt7Dg55JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55z5ND1D/SP+Kq1ri5jH+qs+f9Xz/qP84ok0PUP9I/4qrWuLmMf6qz5/1fP+o/zirV+39feTHk01XT/wBt/ulfRn/4mfij/SLz/kKw9YOv+jWvJ+Tr7ew4OediR/8AX/6Ref6+M8wdfucn5Ovt7Dg555rStFv21HxKB4l1dSmqwKxEdpmQ/Z7U7jmDqMgcYGFHGck6smh6h/pH/FVa1xcxj/VWfP8Aq+f9R/nFRC9tv6v6le5darp/7b/dK/i1/wDiV/8AHxef8hXTzzB1/wBJt+T8nX29hwc87Ej/AOv/ANIvP9fGeYOv3OT8nX29hwc8814p0a/j05i/iXV5R/atguHjtMZNxbgNxAORkEdsgZBGQdWTQ9Q/0j/iqta4uYx/qrPn/V8/6j/OKFfm27f1uC5OVar+uX+7/X5aEj/6/wD0i8/18Z5g6/c5Pydfb2HBzzj6M/8AxM/FH+kXn/IVh6wdf9GteT8nX29hwc82JND1D/SP+Kq1ri5jH+qs+f8AV8/6j/OKytK0W/bUfEoHiXV1KarArER2mZD9ntTuOYOoyBxgYUcZySO91p/VvUKfJbddP/bf7p0sj/6//SLz/XxnmDr9zk/J19vYcHPOP4tf/iV/8fF5/wAhXTzzB1/0m35Pydfb2HBzzYk0PUP9I/4qrWuLmMf6qz5/1fP+o/zisrxTo1/HpzF/Euryj+1bBcPHaYybi3AbiAcjII7ZAyCMgk78r0/r7wpcnNHVdP8A23+6dLI/+v8A9IvP9fGeYOv3OT8nX29hwc8kj/6//SLz/XxnmDr9zk/J19vYcHPOfJoeof6R/wAVVrXFzGP9VZ8/6vn/AFH+cUSaHqH+kf8AFVa1xcxj/VWfP+r5/wBR/nFWr9v6+8mPJpqun/tv90r6M/8AxM/FH+kXn/IVh6wdf9GteT8nX29hwc87Ej/6/wD0i8/18Z5g6/c5Pydfb2HBzzzWlaLftqPiUDxLq6lNVgViI7TMh+z2p3HMHUZA4wMKOM5J1ZND1D/SP+Kq1ri5jH+qs+f9Xz/qP84qIXtt/V/Ur3LrVdP/AG3+6V/Fr/8AEr/4+Lz/AJCunnmDr/pNvyfk6+3sODnnYkf/AF/+kXn+vjPMHX7nJ+Tr7ew4Oeea8U6Nfx6cxfxLq8o/tWwXDx2mMm4twG4gHIyCO2QMgjIOrJoeof6R/wAVVrXFzGP9VZ8/6vn/AFH+cUK/Nt2/rcFycq1X9cv93+vy0JH/ANf/AKRef6+M8wdfucn5Ovt7Dg55x9Gf/iZ+KP8ASLz/AJCsPWDr/o1ryfk6+3sODnmxJoeof6R/xVWtcXMY/wBVZ8/6vn/Uf5xWVpWi37aj4lA8S6upTVYFYiO0zIfs9qdxzB1GQOMDCjjOSR3utP6t6hT5Lbrp/wC2/wB06WR/9f8A6Ref6+M8wdfucn5Ovt7Dg55x/Fr/APEr/wCPi8/5CunnmDr/AKTb8n5Ovt7Dg55sSaHqH+kf8VVrXFzGP9VZ8/6vn/Uf5xWV4p0a/j05i/iXV5R/atguHjtMZNxbgNxAORkEdsgZBGQSd+V6f194UuTmjqun/tv906WR/wDX/wCkXn+vjPMHX7nJ+Tr7ew4OeSR/9f8A6Ref6+M8wdfucn5Ovt7Dg55z5ND1D/SP+Kq1ri5jH+qs+f8AV8/6j/OKJND1D/SP+Kq1ri5jH+qs+f8AV8/6j/OKtX7f195MeTTVdP8A23+6V9Gf/iZ+KP8ASLz/AJCsPWDr/o1ryfk6+3sODnnYkf8A1/8ApF5/r4zzB1+5yfk6+3sODnnmtK0W/bUfEoHiXV1KarArER2mZD9ntTuOYOoyBxgYUcZyTqyaHqH+kf8AFVa1xcxj/VWfP+r5/wBR/nFRC9tv6v6le5darp/7b/dK/i1/+JX/AMfF5/yFdPPMHX/Sbfk/J19vYcHPJVLxTo1/HpzF/Euryj+1bBcPHaYybi3AbiAcjII7ZAyCMglLXm+7+tzKo4ckdV/Sj/dP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial myocardial activation is normal; thus, there is a normal septal q wave in leads 1 and V6, followed by a tall R wave. Similarly, there is a normal initial septal R wave followed by a deep S wave in leads aVR and V1. However, the subsequent abnormal right ventricular activation occurs from left to right and goes through the ventricular myocardium instead of the His-Purkinje system; thus, there will be a tall and broad secondary R wave (R') in leads aVR and V1 (a RSR' complex), and a deep and broad S wave in leads I and V6. The width of the QRS complex is &gt;0.12 sec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7909=[""].join("\n");
var outline_f7_46_7909=null;
var title_f7_46_7910="Normal BP girls";
var content_f7_46_7910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blood pressure levels for girls by age and height percentile",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"16\" width=\"6%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Age",
"        <br/>",
"        (year)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        BP",
"        <br/>",
"        (percentile)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Systolic BP (mmHg)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Diastolic BP (mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"7\">",
"        Percentile of height",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"7\">",
"        Percentile of height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        5",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        10",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        25",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        75",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        5",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        10",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        25",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        75",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        1",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        2",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        3",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        4",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        5",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        6",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        7",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        8",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        9",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        10",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        11",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        12",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        13",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        14",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        15",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        16",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        17",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile is 1.28 standard deviation, 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile is 1.645 standard deviation, and the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile is 2.326 over the mean.",
"    <div class=\"footnotes\">",
"     BP: blood pressure.",
"    </div>",
"    <div class=\"reference\">",
"     From: the Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute. National Institutes of Health. May 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7910=[""].join("\n");
var outline_f7_46_7910=null;
var title_f7_46_7911="Flurbiprofen (systemic): Pediatric drug information";
var content_f7_46_7911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurbiprofen (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30008?source=see_link\">",
"    see \"Flurbiprofen (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/35/36405?source=see_link\">",
"    see \"Flurbiprofen (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8101425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8101443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Flurbiprofen;",
"     </li>",
"     <li>",
"      Ansaid&reg;;",
"     </li>",
"     <li>",
"      Apo-Flurbiprofen&reg;;",
"     </li>",
"     <li>",
"      Froben-SR&reg;;",
"     </li>",
"     <li>",
"      Froben&reg;;",
"     </li>",
"     <li>",
"      Novo-Flurprofen;",
"     </li>",
"     <li>",
"      Nu-Flurprofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10481875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10482278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30008?source=see_link\">",
"      see \"Flurbiprofen (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Arthritis: 200-300 mg/day in 2-4 divided doses; maximum dose: 100 mg/dose; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dysmenorrhea: 50 mg 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8101571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8101445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8101438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085913.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085913.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10482280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food, milk, or antacid to decrease GI effects.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10482013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of inflammatory disease and rheumatoid disorders, dysmenorrhea, pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8101437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flurbiprofen may be confused with fenoprofen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ansaid&reg; may be confused with Asacol&reg;, Axid&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8101496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, anxiety, depression, dizziness, headache, insomnia, malaise, nervousness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, nausea, vomiting, weight changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Reflexes increased, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Vision changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic reaction, anemia, angioedema, asthma, bruising, cerebrovascular ischemia, CHF, confusion, eczema, eosinophilia, epistaxis, exfoliative dermatitis, fever, gastric/peptic ulcer, hematocrit increased, hematuria, hemoglobin decreased, hepatitis, hypertension, hyperuricemia, interstitial nephritis, jaundice, leukopenia, paresthesia, parosmia, photosensitivity, pruritus, purpura, renal failure, stomatitis, thrombocytopenia, toxic epidermal necrolysis, urticaria, vasodilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10482014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flurbiprofen or any component; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10482264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in renal or hepatic impairment, GI disease, cardiac disease, and patients receiving anticoagulants.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10482015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new-onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin's cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy, and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the \"aspirin triad\" who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8101509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8101510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10482275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate but not the extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8101488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8101489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies flurbiprofen as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10482281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, platelets, BUN, serum creatinine, liver enzymes, occult blood loss",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10482276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10482277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Within 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 95% in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F11431965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/35/36405?source=see_link\">",
"      see \"Flurbiprofen (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral use: Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of flurbiprofen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Flurbiprofen may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; palpitations; or weight gain.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15992 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-518C2F532B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7911=[""].join("\n");
var outline_f7_46_7911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101425\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101443\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481875\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482278\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101571\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101445\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101438\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482280\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482013\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101437\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101496\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482014\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482264\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482015\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101509\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101510\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482275\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101488\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101489\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482281\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482276\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482277\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431965\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/29/22995?source=related_link\">",
"      Flurbiprofen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/3/38963?source=related_link\">",
"      Flurbiprofen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/61/42962?source=related_link\">",
"      Flurbiprofen (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30008?source=related_link\">",
"      Flurbiprofen (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/35/36405?source=related_link\">",
"      Flurbiprofen (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_46_7912="Urticaria annular lesions";
var content_f7_46_7912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60454%7EDERM%2F63996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60454%7EDERM%2F63996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular, edematous, mildly erythematous plaques are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple mildly erythematous and edematous plaques are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7912=[""].join("\n");
var outline_f7_46_7912=null;
var title_f7_46_7913="Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)";
var content_f7_46_7913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/46/7913/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/46/7913/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/46/7913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/46/7913/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/46/7913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/46/7913/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/46/7913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a disorder of impaired water excretion caused by the inability to suppress the secretion of antidiuretic hormone (ADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1\">",
"     1",
"    </a>",
"    ]. If water intake exceeds the reduced urine output, the ensuing water retention leads to the development of hyponatremia.",
"   </p>",
"   <p>",
"    The SIADH should be suspected in any patient with hyponatremia, hypoosmolality, and a urine osmolality above 100",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    In SIADH, the urine sodium concentration is usually above 40",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the serum potassium concentration is normal, there is no acid-base disturbance, and the serum uric acid concentration is frequently low [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology and etiology of SIADH will be reviewed here. The treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis of hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma sodium concentration (PNa) is a function of the ratio of the body's content of exchangeable sodium and potassium (Na",
"    <sub>",
"     E",
"    </sub>",
"    and K",
"    <sub>",
"     E",
"    </sub>",
"    ) and total body water (TBW) as described by Edelman's classic equation:",
"   </p>",
"   <p>",
"    &nbsp;PNa &nbsp;&asymp; &nbsp;Na",
"    <sub>",
"     E",
"    </sub>",
"    +",
"    <span class=\"nowrap\">",
"     K",
"     <sub>",
"      E",
"     </sub>",
"     /Total",
"    </span>",
"    body water",
"   </p>",
"   <p>",
"    Antidiuretic hormone (ADH, arginine vasopressin) secretion results in a concentrated urine and therefore a reduced urine volume. The higher the plasma ADH, the more concentrated the urine. In most patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), ingestion of water does not adequately suppress ADH, and the urine remains concentrated. This leads to water retention, which increases TBW. This increase in TBW lowers the plasma sodium concentration by dilution (see above equation) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the increase in TBW transiently expands the extracellular fluid volume and thereby triggers increased urinary sodium excretion, which both returns the extracellular fluid volume toward normal and further lowers the plasma sodium concentration.",
"   </p>",
"   <p>",
"    Hyponatremia can occur in SIADH even if the only fluid given is isotonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/2\">",
"     2",
"    </a>",
"    ]. The mechanism by which this occurs and why isotonic saline administration can lower the plasma sodium concentration in patients with SIADH and a highly concentrated urine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Intravenous saline'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patterns of ADH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal individuals, plasma ADH levels are very low when the plasma osmolality is below 280 mosmol",
"    <span class=\"nowrap\">",
"     /kg,",
"    </span>",
"    thereby permitting the excretion of ingested water, and ADH levels increase progressively as the plasma osmolality rises above 280",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ADH regulation is impaired in SIADH; four different patterns have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type A is characterized by erratic, unregulated release of ADH that varies widely with no relation to the plasma osmolality. Plasma ADH levels are often above that required for maximum antidiuresis, so the urine osmolality is typically very high.",
"     </li>",
"     <li>",
"      Type B is characterized by a modest and constant leak of ADH.",
"     </li>",
"     <li>",
"      Type C, characterized by downward resetting of the osmostat, is a variant of SIADH in which the plasma sodium concentration is normally regulated (and is therefore stable) at a lower level, typically between 125 and 135",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Establishing the presence of this condition is important because, unlike other forms of SIADH, there is no need to be concerned that the plasma sodium will continue to fall without therapy. This disorder is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Reset osmostat'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type D, the least common, is characterized by normal osmoregulation (ie, ADH secretion varies appropriately with the plasma osmolality), but the urine is concentrated even if ADH release is suppressed. At least one mechanism by which this occurs is a germ cell mutation in which the V2 vasopressin receptor is constituently activated [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/3\">",
"       3",
"      </a>",
"      ]. Other potential mechanisms include production of an antidiuretic compound other than immunoreactive arginine vasopressin and a postreceptor defect in trafficking of aquaporin-2 water channels, which mediate ADH-induced antidiuresis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hereditary SIADH'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Determinants of urine output",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the persistent secretion of ADH, there are two other potentially important determinants of the urine output in patients with SIADH: the rate of solute excretion and partial escape from the effect of ADH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Solute excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, the urine output is primarily determined by water intake. Changes in water intake lead to alterations in the plasma osmolality that are sensed by the osmoreceptors in the hypothalamus that regulate both ADH release and thirst. As an example, an increase in water intake sequentially lowers the plasma osmolality, decreases ADH secretion, and reduces collecting tubule permeability to water; the net effect is the rapid excretion of the excess water in a dilute urine.",
"   </p>",
"   <p>",
"    In SIADH, however, an increase in water intake does not produce an increase in water excretion because ADH release is relatively fixed. Suppose that a patient has moderately severe SIADH with a urine osmolality that cannot be reduced below 750",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (the normal minimum urine osmolality is 40 to 100",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"    In this patient, the urine output is determined by the rate of excretion of solutes (primarily sodium and potassium salts and urea). Now suppose this patient consumes a typical Western diet containing approximately 750 mosmol of solute, all of which are excreted in the urine each day. With a fixed urine osmolarity of 750",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    the daily urine output will be only one liter (750 &divide; 750 = 1), and it will not increase in response to increased water intake.",
"   </p>",
"   <p>",
"    One way to increase water excretion in this hypothetical patient with SIADH is to prescribe a high salt and protein diet without a increase in water ingestion. If, for example, the solute intake and therefore solute excretion rose to 1200",
"    <span class=\"nowrap\">",
"     mosmol/day,",
"    </span>",
"    the urine output would increase to 1.6",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (1200 &divide; 750 = 1.6). The increase in water excretion would then tend to raise the plasma sodium concentration toward normal.",
"   </p>",
"   <p>",
"    Similar considerations concerning the role of solute intake apply when ADH effect is relatively fixed at a low level in central or nephrogenic diabetes insipidus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6691?source=see_link\">",
"     \"Urine output in diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Escape from the effect of ADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in experimental animals given ADH and water have shown an initial phase of water retention and hyponatremia followed by partial escape from the antidiuresis so that, despite persistently high levels of ADH, urine osmolality decreases. When the urine osmolality falls, water excretion increases, matching water intake, and the plasma sodium concentration tends to stabilize [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A similar response appears to occur in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This escape from ADH-induced antidiuresis appears to be mediated by decreased expression of aquaporin-2, the ADH-sensitive water channel in the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/9\">",
"     9",
"    </a>",
"    ]. The regulation of aquaporin-2 in this setting appears to be unrelated to plasma or tissue osmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the following causes of persistent antidiuretic hormone (ADH) release is likely to be present in patients who fulfill the clinical criteria for the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     CNS disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any CNS disorder, including stroke, hemorrhage, infection, trauma, and psychosis, can enhance ADH release. A discussion of the disturbances in water balance that may occur in patients with mental illness and a brief review of the antidiuretic action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , a drug that can cause an SIADH picture, are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in other causes of SIADH, hyponatremia associated with intracranial bleeding, as well as other severe neurologic events, is due to ADH-mediated water retention and to urinary sodium losses. However, with these severe neurological conditions, there is uncertainty as to whether the sodium losses are a result of SIADH-induced expansion of the extracellular volume or whether they are caused by salt wasting (ie, cerebral salt wasting), with release of ADH that is secondary to a reduction in extracellular fluid volume. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Cerebral salt wasting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of this uncertainty, therapy of hyponatremia in patients with CNS disorders usually requires the administration of hypertonic saline, rather than fluid restriction or isotonic saline (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Cerebral salt wasting'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic production of ADH by a tumor is most often due to a small cell carcinoma of the lung and is rarely seen with other lung tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Less common causes of malignancy-associated SIADH include head and neck cancer, olfactory neuroblastoma (esthesioneuroblastoma), and extrapulmonary small cell carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ectopic ADH secretion by tumor cells has been documented in vitro. In addition, some small cell lung cancer cells increase ADH secretion in response to high osmolality, suggesting a degree of regulation of the ectopic secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/17\">",
"     17",
"    </a>",
"    ]. This in vitro finding is compatible with the clinical observation that some patients with tumor-induced SIADH show evidence of osmoregulation of ADH release [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs can enhance ADH release or effect, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    (a derivative of carbamazepine), high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and selective serotonin reuptake inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1,18-26\">",
"     1,18-26",
"    </a>",
"    ]. Experimental studies suggest that chlorpropamide may increase concentrating ability both by increasing sodium chloride reabsorption in the loop of Henle (thereby enhancing the efficiency of countercurrent exchange) and by augmenting collecting tubule permeability to water [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/19\">",
"     19",
"    </a>",
"    ]. The latter effect may be mediated by an increased number of ADH receptors in the collecting tubule cells. Carbamazepine and oxcarbazepine also act at least in part by increasing the sensitivity to ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/20,21,24\">",
"     20,21,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SIADH due to high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be a particular problem since patients receiving this regimen are often fluid loaded to prevent hemorrhagic cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. As a result, marked water retention and potentially fatal hyponatremia may ensue in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/25\">",
"     25",
"    </a>",
"    ]. This complication has been primarily described with doses in the range of 30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    used to treat malignancy, or 6",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as given in the STAMP protocol in preparation for bone marrow rescue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/26\">",
"     26",
"    </a>",
"    ]. Although less common, hyponatremia can also occur with the lower doses (10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    that are given as pulse therapy in autoimmune diseases such as lupus nephritis. Chemotherapy-induced nausea may play a contributory role since nausea is a potent stimulus to ADH release. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link&amp;anchor=H12#H12\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\", section on 'Other factors affecting ADH secretion'",
"    </a>",
"    .) The fall in the plasma sodium concentration in this setting can be minimized by using isotonic saline rather than free water to maintain a high urine output.",
"   </p>",
"   <p>",
"    SIADH is also associated with the selective serotonin reuptake inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The exact prevalence is unknown; patients above age 65 years may be more susceptible to the complication [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many other drugs have been associated with the SIADH. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"     thiothixene",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , monoamine oxidase inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , opiates, nonsteroidal antiinflammatory agents, interferon-alpha, interferon-gamma, sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , lorcainide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , and \"ecstasy\" (methylenedioxymethamphetamine), a drug of abuse that may also be associated with excessive water intake [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1,27,32-36\">",
"     1,27,32-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical procedures are often associated with hypersecretion of ADH, a response that is probably mediated by pain afferents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. In addition, hyponatremia may develop after other types of interventional procedures, such as cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyponatremia is also a common late complication of",
"    <strong>",
"     transsphenoidal",
"    </strong>",
"    pituitary surgery, occurring in 21 to 35 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Although relative cortisol deficiency may contribute, the major cause is inappropriate ADH release from the injured posterior pituitary gland. The fall in the plasma sodium concentration is most severe on the sixth to seventh postoperative day. This form of isolated hyponatremia (or isolated second phase) appears to be a subset of the classic",
"    <strong>",
"     triphasic",
"    </strong>",
"    cycle in which initial polyuria is followed by transient SIADH and then either recovery or, in severe cases, a third phase of permanent central diabetes insipidus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\", section on 'Neurosurgery or trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, hyponatremia after pituitary surgery is due to cerebral salt wasting (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Cerebral salt wasting'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary diseases, particularly pneumonia (viral, bacterial, tuberculous), can lead to the SIADH, although the mechanism by which this occurs is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/38\">",
"     38",
"    </a>",
"    ]. A similar response may infrequently be seen with asthma, atelectasis, acute respiratory failure, and pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1,38\">",
"     1,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hormone deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both hypopituitarism and hypothyroidism may be associated with hyponatremia and an SIADH picture that can be corrected by hormone replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H88313973#H88313973\">",
"     \"Causes of hyponatremia\", section on 'Hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hormone administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SIADH can by induced by exogenous hormone administration, as with vasopressin (to control gastrointestinal bleeding),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP, to treat von Willebrand disease or hemophilia or platelet dysfunction), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    (to induce labor) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. As with vasopressin and desmopressin, oxytocin acts by increasing the activity of the V2 (antidiuretic) vasopressin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common cause of hyponatremia is symptomatic HIV infection, either the acquired immune deficiency syndrome (AIDS) or early symptomatic HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/48\">",
"     48",
"    </a>",
"    ]. Although volume depletion (due, for example, to gastrointestinal losses) or adrenal insufficiency may be responsible, many patients have the SIADH. Pneumonia, due to Pneumocystis carinii or other organisms, central nervous system infections, and malignant disease, are most often responsible in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=see_link\">",
"     \"Electrolyte disturbances with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hereditary SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical picture of SIADH may result from genetic disorders that result in antidiuresis. At least two genetic abnormalities have been identified, one affecting the gene for the renal vasopressin-2 (V2) receptor, which some investigators have named nephrogenic syndrome of inappropriate antidiuresis, and one affecting osmolality sensing in the hypothalamus.",
"   </p>",
"   <p>",
"    In the initial description of the nephrogenic syndrome, two male infants were described who presented with hyponatremia, hypoosmolality, increased urine osmolality, and a high urine sodium concentration consistent with SIADH, but with no detectable circulating ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Gain-of-function mutations were found in the gene encoding the V2 receptor that mediates the antidiuretic response to ADH; persistent activation of the receptor was responsible for the persistent antidiuretic state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/51\">",
"     51",
"    </a>",
"    ]. The gene for the V2 receptor is located on the X chromosome, and loss-of-function mutations of the gene are responsible for X-linked nephrogenic diabetes insipidus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hereditary nephrogenic DI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nephrogenic syndrome of inappropriate antidiuresis has also been found in adult men and women. In one study, a 74-year-old man with an initial diagnosis of SIADH was unresponsive to oral inhibitors of the V2 receptor; he was subsequently discovered to have a gain-of-function mutation of the gene for this receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/52\">",
"     52",
"    </a>",
"    ]. After screening of family members, two additional hemizygous males and four heterozygous females were identified. Spontaneous episodes of hyponatremia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an abnormal water-load test were observed in all but one woman with the genetic defect, who had preferential inactivation of the X chromosome harboring the mutated allele.",
"   </p>",
"   <p>",
"    The hereditary hypothalamic syndrome is due to a mutation in the transient receptor potential vanilloid type 4 (TRPV4) gene, which encodes a component of the central osmolality-sensing mechanism in the hypothalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/53\">",
"     53",
"    </a>",
"    ]. A loss-of-function polymorphism in this gene interferes with sensing of hypoosmolality and therefore interferes with appropriate suppression of ADH release in the presence of hypoosmolality. Thus, affected individuals behave as if they have a reset osmostat, as the serum sodium is modestly reduced (mean 136",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in this family) and regulated normally around that value. Thus, in the absence of a superimposed disease, there is no risk of progressive hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Reset osmostat'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic SIADH has been described primarily in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. However, some cases of apparently idiopathic disease were later found to be caused by an occult tumor (most often small cell carcinoma or olfactory neuroblastoma) and, in older patients, giant cell (temporal) arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7913/abstract/1,55,58,59\">",
"     1,55,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CEREBRAL SALT WASTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare syndrome has been described in patients with cerebral disease (particularly subarachnoid hemorrhage) that mimics all of the findings in the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) except that salt wasting is thought to be the primary defect, with the ensuing volume depletion causing a secondary rise in antidiuretic hormone (ADH) release. This distinction is not always easy to make since the true volume status of the patient is sometimes difficult to ascertain. The pathogenesis, manifestations, and treatment of cerebral salt wasting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=see_link\">",
"     \"Cerebral salt-wasting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13777?source=see_link\">",
"       \"Patient information: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3609886\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a disorder of impaired water excretion caused by the inability to suppress the secretion of antidiuretic hormone (ADH). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SIADH should be suspected in any patient with hyponatremia, hypoosmolality, and a urine osmolality above 100",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"      In SIADH, the urine sodium concentration is usually above 40",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      the serum potassium concentration is normal, there is no acid-base disturbance, and the serum uric acid concentration is frequently low. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ADH secretion results in a concentrated urine and therefore a reduced urine volume. In most patients with SIADH, ingestion of water does not adequately suppress ADH, and the urine remains concentrated. This leads to water retention, which increases total body water (TBW). This increase in TBW lowers the plasma sodium concentration by dilution. In addition, the increase in TBW transiently expands the extracellular fluid volume and thereby triggers increased urinary sodium excretion, which both returns the extracellular fluid volume toward normal and further lowers the plasma sodium concentration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the following causes of persistent ADH release is likely to be present in patients who fulfill the clinical criteria for the SIADH (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Any CNS disorder, including stroke, hemorrhage, infection, trauma, and psychosis can enhance ADH release. There is uncertainty as to whether hyponatremia in patients with severe neurologic disorders (such as hemorrhage or trauma) is due to SIADH or salt wasting (ie, cerebral salt wasting). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'CNS disturbances'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Cerebral salt wasting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectopic production of ADH by a tumor is most often due to a small cell carcinoma of the lung and is rarely seen with other lung tumors. Less common causes of malignancy-associated SIADH include head and neck cancer, olfactory neuroblastoma (esthesioneuroblastoma), and extrapulmonary small cell carcinomas. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain drugs can enhance ADH release or effect, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      (a derivative of carbamazepine), high-dose intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and selective serotonin reuptake inhibitors. Many other drugs have been associated with the SIADH. These include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"       thiothixene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"       thioridazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      , monoamine oxidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , opiates, nonsteroidal antiinflammatory agents, interferon-alpha, interferon-gamma, sodium",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      , lorcainide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , and high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . \"Ecstasy\" (methylenedioxymethamphetamine) is a drug of abuse that may also be associated with both SIADH and excessive water intake. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical procedures are often associated with hypersecretion of ADH, a response that is probably mediated by pain afferents. In addition, hyponatremia may develop after other interventional medical procedures, such as cardiac catheterization. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary diseases, particularly pneumonia (viral, bacterial, tuberculous), can lead to the SIADH, although the mechanism by which this occurs is not clear. A similar response may infrequently be seen with asthma, atelectasis, acute respiratory failure, and pneumothorax. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both hypopituitarism and hypothyroidism may be associated with hyponatremia and clinical findings identical to SIADH, but these abnormalities are corrected by hormone replacement. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hormone deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SIADH can by induced by exogenous administration of hormones: vasopressin (to control gastrointestinal bleeding); ADH analogs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      (dDAVP, to treat von Willebrand disease, hemophilia, other forms of platelet dysfunction, or enuresis); or other hormones with antidiuretic effects, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (to induce labor). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hormone administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic HIV infection is associated with SIADH. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical picture of SIADH may result from genetic disorders that result in antidiuresis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hereditary SIADH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.703.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/2\">",
"      Steele A, Gowrishankar M, Abrahamson S, et al. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med 1997; 126:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/3\">",
"      Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006; 119:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/4\">",
"      Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/5\">",
"      Verbalis JG, Drutarosky MD. Adaptation to chronic hypoosmolality in rats. Kidney Int 1988; 34:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/6\">",
"      Gross PA, Anderson RJ. Effects of DDAVP and AVP on sodium and water balance in conscious rat. Am J Physiol 1982; 243:R512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/7\">",
"      LEAF A, BARTTER FC, SANTOS RF, WRONG O. Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention. J Clin Invest 1953; 32:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/8\">",
"      JAENIKE JR, WATERHOUSE C. The renal response to sustained administration of vasopressin and water in man. J Clin Endocrinol Metab 1961; 21:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/9\">",
"      Ecelbarger CA, Nielsen S, Olson BR, et al. Role of renal aquaporins in escape from vasopressin-induced antidiuresis in rat. J Clin Invest 1997; 99:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/10\">",
"      Murase T, Ecelbarger CA, Baker EA, et al. Kidney aquaporin-2 expression during escape from antidiuresis is not related to plasma or tissue osmolality. J Am Soc Nephrol 1999; 10:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/11\">",
"      Saito T, Higashiyama M, Nagasaka S, et al. Role of aquaporin-2 gene expression in hyponatremic rats with chronic vasopressin-induced antidiuresis. Kidney Int 2001; 60:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/12\">",
"      Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/13\">",
"      Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997; 156:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/14\">",
"      Ferlito A, Rinaldo A, Devaney KO. Syndrome of inappropriate antidiuretic hormone secretion associated with head neck cancers: review of the literature. Ann Otol Rhinol Laryngol 1997; 106:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/15\">",
"      Talmi YP, Wolf GT, Hoffman HT, Krause CJ. Elevated arginine vasopressin levels in squamous cell cancer of the head and neck. Laryngoscope 1996; 106:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/16\">",
"      S&oslash;rensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995; 238:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/17\">",
"      Kim JK, Summer SN, Wood WM, Schrier RW. Osmotic and non-osmotic regulation of arginine vasopressin (AVP) release, mRNA, and promoter activity in small cell lung carcinoma (SCLC) cells. Mol Cell Endocrinol 1996; 123:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/18\">",
"      Weissman PN, Shenkman L, Gregerman RI. Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic-hormone activity. N Engl J Med 1971; 284:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/19\">",
"      Hensen J, Haenelt M, Gross P. Water retention after oral chlorpropamide is associated with an increase in renal papillary arginine vasopressin receptors. Eur J Endocrinol 1995; 132:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/20\">",
"      Gold PW, Robertson GL, Ballenger JC, et al. Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab 1983; 57:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/21\">",
"      Kamiyama T, Iseki K, Kawazoe N, et al. Carbamazepine-induced hyponatremia in a patient with partial central diabetes insipidus. Nephron 1993; 64:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/22\">",
"      Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/23\">",
"      Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res 1988; 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/24\">",
"      Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002; 51:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/25\">",
"      Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/26\">",
"      Salido M, Macarron P, Hern&aacute;ndez-Garc&iacute;a C, et al. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus 2003; 12:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/27\">",
"      ten Holt WL, van Iperen CE, Schrijver G, Bartelink AK. Severe hyponatremia during therapy with fluoxetine. Arch Intern Med 1996; 156:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/28\">",
"      Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996; 155:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/29\">",
"      Covyeou JA, Jackson CW. Hyponatremia associated with escitalopram. N Engl J Med 2007; 356:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/30\">",
"      Ozturk S, Ozsenel EB, Kazancioglu R, Turkmen A. A case of fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion. Nat Clin Pract Nephrol 2008; 4:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/31\">",
"      Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med 2004; 164:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/32\">",
"      Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after \"ecstasy\" (3,4-MDMA). Lancet 1996; 347:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/33\">",
"      Wilkins B. Cerebral oedema after MDMA (\"ecstasy\") and unrestricted water intake. Hyponatraemia must be treated with low water input. BMJ 1996; 313:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/34\">",
"      Adler D, Voide C, Thorens JB, Desmeules J. SIADH consecutive to ciprofloxacin intake. Eur J Intern Med 2004; 15:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/35\">",
"      Liapis K, Apostolidis J, Charitaki E, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. Ann Pharmacother 2008; 42:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/36\">",
"      Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis 2008; 52:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/37\">",
"      Fieldman NR, Forsling ML, Le Quesne LP. The effect of vasopressin on solute and water excretion during and after surgical operations. Ann Surg 1985; 201:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/38\">",
"      Anderson RJ. Hospital-associated hyponatremia. Kidney Int 1986; 29:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/39\">",
"      Gowrishankar M, Lin SH, Mallie JP, et al. Acute hyponatremia in the perioperative period: insights into its pathophysiology and recommendations for management. Clin Nephrol 1998; 50:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/40\">",
"      Aronson D, Dragu RE, Nakhoul F, et al. Hyponatremia as a complication of cardiac catheterization: a prospective study. Am J Kidney Dis 2002; 40:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/41\">",
"      Sane T, Rantakari K, Poranen A, et al. Hyponatremia after transsphenoidal surgery for pituitary tumors. J Clin Endocrinol Metab 1994; 79:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/42\">",
"      Olson BR, Rubino D, Gumowski J, Oldfield EH. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab 1995; 80:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/43\">",
"      Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/44\">",
"      Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/45\">",
"      Humphries JE, Siragy H. Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 1993; 44:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/46\">",
"      Feeney JG. Water intoxication and oxytocin. Br Med J (Clin Res Ed) 1982; 285:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/47\">",
"      Li C, Wang W, Summer SN, et al. Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol 2008; 19:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/48\">",
"      Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA 1990; 263:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/49\">",
"      Gitelman SE, Feldman BJ, Rosenthal SM. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients. Am J Med 2006; 119:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/50\">",
"      Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005; 352:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/51\">",
"      Carpentier E, Greenbaum LA, Rochdi D, et al. Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. J Am Soc Nephrol 2012; 23:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/52\">",
"      Decaux G, Vandergheynst F, Bouko Y, et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007; 18:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/53\">",
"      Tian W, Fu Y, Garcia-Elias A, et al. A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia. Proc Natl Acad Sci U S A 2009; 106:14034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/54\">",
"      Goldstein CS, Braunstein S, Goldfarb S. Idiopathic syndrome of inappropriate antidiuretic hormone secretion possibly related to advanced age. Ann Intern Med 1983; 99:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/55\">",
"      Sterns RH. The syndrome of inappropriate antidiuretic hormone secretion of unknown origin. Am J Kidney Dis 1999; 33:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/56\">",
"      Miller M, Hecker MS, Friedlander DA, Carter JM. Apparent idiopathic hyponatremia in an ambulatory geriatric population. J Am Geriatr Soc 1996; 44:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/57\">",
"      Anpalahan M. Chronic idiopathic hyponatremia in older people due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) possibly related to aging. J Am Geriatr Soc 2001; 49:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/58\">",
"      Inappropriate antidiuretic hormone secretion of unknown origin. Kidney Int 1980; 17:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7913/abstract/59\">",
"      Gentric A, Baccino E, Mottier D, et al. Temporal arteritis revealed by a syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1988; 85:559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2384 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7913=[""].join("\n");
var outline_f7_46_7913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3609886\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patterns of ADH secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Determinants of urine output",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Solute excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Escape from the effect of ADH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CNS disturbances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hormone administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hereditary SIADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CEREBRAL SALT WASTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3609886\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2384|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 1\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=related_link\">",
"      Cerebral salt-wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39332?source=related_link\">",
"      Electrolyte disturbances with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13777?source=related_link\">",
"      Patient information: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6691?source=related_link\">",
"      Urine output in diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_46_7914="Organic acidemias";
var content_f7_46_7914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Organic acidemias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/46/7914/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/46/7914/contributors\">",
"     Olaf A Bodamer, MD, FACMG, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/46/7914/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/46/7914/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/46/7914/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/46/7914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/46/7914/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/46/7914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organic acidemias, also known as organic acidurias, are a group of disorders characterized by increased excretion of organic acids in urine. They result primarily from deficiencies of specific enzymes in the breakdown pathways of amino acids or from enzyme deficiencies in beta oxidation of fatty acids or carbohydrate metabolism. Abnormal organic acid levels also are found in the urine of some patients with mitochondrial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most organic acidemias become clinically apparent during the newborn period or early infancy. After an initial period of well-being, affected children develop a life-threatening episode of metabolic acidosis characterized by an increased anion gap. This presenting episode may be mistaken for sepsis, and if unrecognized, is associated with significant mortality.",
"   </p>",
"   <p>",
"    Children with an organic acidemia are susceptible to metabolic decompensation during episodes of increased catabolism, such as intercurrent illness, trauma, surgery, or prolonged episodes of fasting. Parents and clinicians must be well informed about the initial signs of decompensation and trained in applying an emergency regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Surgeons and anesthesiologists should be aware of potential complications and their prevention during anesthesia and surgery.",
"   </p>",
"   <p>",
"    Diagnosis has been facilitated through the use of gas chromatograph-mass spectrometry (GC-MS) and tandem mass spectrometry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/4\">",
"     4",
"    </a>",
"    ]. Prenatal diagnosis is available for most disorders by detection of diagnostic compounds in amniotic fluid; by analysis of enzyme activities in amniocytes or chorionic villi; by molecular analysis; or by a combination of the three [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/5\">",
"     5",
"    </a>",
"    ]. Diagnosis also may be made through newborn screening by tandem mass spectrometry, which is available in all states of the United States, Australia, and many European and Asian countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organic acidemias can be classified into five categories [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Branched-chain organic acidemias, discussed below (",
"      <a class=\"graphic graphic_figure graphicRef53127 \" href=\"UTD.htm?32/14/33005\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65861 \" href=\"UTD.htm?12/8/12430\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Multiple carboxylase deficiency, including holocarboxylase synthetase deficiency and biotinidase deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the hereditary ataxias\", section on 'Disorders of pyruvate and lactate metabolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glutaric aciduria type I and related organic acidemias, discussed below.",
"     </li>",
"     <li>",
"      Fatty acid oxidation defects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"       \"Causes of metabolic myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disorders of energy metabolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The more prevalent organic acidemias are reviewed here: methylmalonic aciduria, propionic acidemia, isovaleric acidemia, 3-methylcrotonyl glycinuria, 3-methylglutaconic aciduria, and glutaric aciduria type I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMMON FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before addressing the individual disorders, considering the common features of clinical presentation, diagnosis, and management is useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with organic acidemia typically present during the first one to two weeks after birth with poor feeding, vomiting, increasing lethargy that progresses to coma, floppiness, and muscular hypotonia. Pregnancy and perinatal history frequently are uncomplicated. Family history may reveal consanguinity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    siblings who died during the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial presentation in older infants or children may include lethargy, vomiting, failure to thrive, or seizures, and an acute decompensation associated with an intercurrent illness resulting in severe metabolic acidosis, hyperammonemia, and ketosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of an infant with suspected organic acidemia includes measurement of pH, carbon dioxide tension, bicarbonate, ammonia, lactate, pyruvate, glucose, electrolytes, creatinine, urea, and ketones. Infants typically have severe metabolic acidosis with an increased anion gap, ketosis, and hyperammonemia. Other common findings include hypoglycemia and electrolyte and other abnormalities associated with volume depletion. A complete blood count and differential are performed to detect neutropenia, thrombocytopenia, or pancytopenia, which occur frequently because of bone marrow suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link\">",
"     \"Approach to the child with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management consists of treatment of the metabolic decompensation, followed by continuing care after recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The initial management includes intravenous hydration and correction of metabolic acidosis, hyperammonemia, hypoglycemia, and electrolyte abnormalities. Other associated illnesses, such as infections, also are treated.",
"   </p>",
"   <p>",
"    These children usually require intravenous therapy during an acute decompensation because nausea and vomiting make oral intake unlikely. Protein is withheld for 24 to a maximum of 48 hours during the acute illness and reintroduced as a low-protein diet, as discussed below. Hydration is started intravenously at 1.25 to 1.5 times maintenance with a solution that provides glucose at an infusion rate based on the estimated hepatic glucose production rate for age. We typically start with the following glucose infusion rates, depending upon age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/11\">",
"     11",
"    </a>",
"    ], and increase as tolerated:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Full-term newborns and infants up to one year of age: 6 to 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per min",
"     </li>",
"     <li>",
"      Children one to six years: 6 to 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per min",
"     </li>",
"     <li>",
"      Children 6 to 12 years: 4 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per min",
"     </li>",
"     <li>",
"      Adolescents (older than 12 years): 2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per min",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The maximum blood glucose concentration should not exceed 130",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Insulin supplementation may be needed in some instances to avoid hyperglycemia and to promote protein synthesis. Acidosis is corrected with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . Patients with persistent severe acidosis (because hypernatremia or volume overload limit the amount of bicarbonate that can be given) or hyperammonemia may need hemodialysis or hemofiltration. Peritoneal dialysis is obsolete [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within one to two days after the initiation of therapy, a specific low-protein diet is introduced gradually over the next two to three days to achieve the minimum protein required for growth and development. This diet should be supplemented with an amino acid mixture that excludes the offending amino acids. If the infant remains dependent upon parenteral nutrition, an amino acid mixture providing a minimum of 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of protein is given to avoid catabolism. Sufficient energy should be provided with carbohydrate and fat, and the amount of protein should be increased if tolerated. Long fasts are avoided. In children, for example, a late-night snack",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    early breakfast are given to limit the duration of overnight fasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are given to reduce the formation or increase the excretion of toxic metabolites. Plasma",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    levels are usually low in patients with organic acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (200 to 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV or 200 to 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in three doses PO) is given to enhance the formation and excretion of acylcarnitine conjugates thought to be toxic to the brain, liver, and kidneys. L-carnitine even at higher doses is generally well tolerated. Multivitamins and calcium supplements also are provided to avoid deficiencies that may result from the low-protein diet.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/49/38675?source=see_link\">",
"     Carglumic acid",
"    </a>",
"    may be considered in cases of methylmalonic aciduria (MMA) and propionic acidemia (PA) when significant hyperammonemia (eg, &gt;400",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/14\">",
"     14",
"    </a>",
"    ]. Accumulation of propionyl-CoA in these disorders leads to reduced synthesis of N-acetyl-glutamate, the physiologic activator of carbamoyl phosphate synthetase 1. Carglumic acid, a molecular analogue, may reduce hyperammonemia through direct activation of carbamoyl phosphate synthetase 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional medications are given for the specific disorders as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be seen at least twice and up to six times per year by a biochemical geneticist familiar with the management of organic acidemias. Infants or those with poor metabolic control are evaluated more frequently. A dietitian experienced in dietary therapy of inborn errors of metabolism should manage the specific low-protein diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     METHYLMALONIC ACIDURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methylmalonic aciduria (MMA, also called methylmalonic acidemia) encompasses a heterogeneous group of disorders that is characterized by impaired metabolism of methylmalonic acid that is generated during the metabolism of certain amino acids (isoleucine, methionine, threonine, or valine) and odd-chain fatty acids (",
"    <a class=\"graphic graphic_figure graphicRef53127 \" href=\"UTD.htm?32/14/33005\">",
"     figure 1",
"    </a>",
"    ). These disorders are caused by a deficiency of the adenosylcobalamin-dependent enzyme methylmalonyl CoA mutase or its cofactor, cobalamin (vitamin B12), which is required for the isomerization of methylmalonyl CoA to succinyl CoA.",
"   </p>",
"   <p>",
"    Methylmalonyl CoA mutase is a dimer of identical subunits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/15\">",
"     15",
"    </a>",
"    ]. The genetic locus has been assigned to chromosome 6p12. At least eight different complementation groups (mut(0), mut(-), cblA, cblB, cblC, cblD, cblF, and cblH) cause MMA. Patients with the mut(0) defect have undetectable mutase activity, whereas those in the mut(-) group have residual, but abnormal activity. The other forms interfere with cofactor formation through defects in the pathway of adenosylcobalamin synthesis (cblA, cblB, and cblH), in the common pathway of cobalamin reduction (cblC and cblD), or in lysosomal cobalamin transport (cblF). The mut(0), mut(-), cbIA, and cbIB defects occur in approximately 30, 10, 30, and 20 percent, respectively, of patients with MMA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. CblC, cblD, and cblF lead to combined MMA and homocystinuria in all cases. CblC and cblF lead to combined MMA and homocystinuria in all cases; cblD may result in MMA, homocystinuria, or combined MMA and homocystinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/17\">",
"     17",
"    </a>",
"    ]. CbIC is the most common among these complementation groups, with more than 100 cases reported throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MMA also can result from cobalamin deficiency. Causes include dietary deficiency, as may occur in vegetarians; impaired intestinal absorption caused by deficiency of intrinsic factor or cubilin, the intestinal receptor that binds the intrinsic factor-cobalamin complex (Imerslund-Gr&auml;sbeck syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/18\">",
"     18",
"    </a>",
"    ]; or deficiency of transcobalamin II, which is required for cobalamin entry into cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=see_link\">",
"     \"Vegetarian diets for children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=see_link\">",
"     \"Physiology of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of MMA is 1:48,000 according to screenings of three- to four-week-old infants in Massachusetts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/19\">",
"     19",
"    </a>",
"    ]. All genetic forms of MMA are inherited as autosomal recessive traits. Thus, MMA occurs more frequently in populations with increased rates of consanguinity. MMA can be detected transiently in some otherwise healthy infants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with MMA mut(0) or MMA mut(-) typically present with the signs of an organic acidemia. The initial presentation in older infants or children with one of the other forms of MMA may include lethargy, seizures, muscular hypotonia, and hypoglycemia during an episode of metabolic decompensation that often is associated with an intercurrent illness. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most patients with cbIC defects present as newborns, with signs similar to those of MMA mut(0) or MMA mut(-). Microcephaly, pigmentary retinopathy, nystagmus, secondary reduced visual acuity, hydrocephalus, or megaloblastic anemia may develop in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. In one report, microcephaly and hydrocephalus were present at birth in 43 and 18 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/20\">",
"     20",
"    </a>",
"    ]. Rarely, affected patients present during childhood or adolescence with the clinical picture of motor neuron disease, lower leg hyposensitivity, and thrombosis. The neurologic symptoms may not be reversible, despite treatment, and can lead to continued gait disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other presenting signs include dehydration and failure to thrive, developmental delay, skin lesions (eg, moniliasis), and occasional hepatomegaly. Some infants with MMA mut(0), MMA mut(-), or cbIC have facial dysmorphism (high forehead; broad nasal bridge; epicanthal folds; long, smooth philtrum; and triangular mouth). This facial dysmorphism also may be observed in patients with PA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Propionic acidemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Asymptomatic benign MMA associated with increased excretion of methylmalonate but with no apparent clinical symptoms has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MMA is made by measurement of organic acids in the urine using gas chromatography-mass spectroscopy (GC-MS). Large amounts of methylmalonic acid, as well as methylcitrate, propionic acid, and 3-OH propionic acid, are present. Measurement of plasma amino acids typically shows elevation of glycine; however, plasma glycine can be normal, even in an infant who previously had abnormal glycine levels. Glycine is not suitable as a metabolic marker since it does not follow metabolic control. In patients with combined MMA and homocystinuria (cblC, cblD, cblF), plasma homocysteine levels are elevated and methionine is often low. The plasma cobalamin concentration typically is normal, and megaloblastic anemia is not seen with the exception of cblC. Vitamin B12 deficiency should be considered in the differential diagnosis of MMA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38983?source=see_link&amp;anchor=H14#H14\">",
"     \"Micronutrient deficiencies associated with malnutrition in children\", section on 'Vitamin B12'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment for MMA consists of a low-protein diet from food sources, such as milk products or meat, that contain the minimum natural protein required for growth (0.5 to 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day). The diet can be supplemented with an amino acid mixture that",
"    <strong>",
"     does not contain",
"    </strong>",
"    isoleucine, methionine, threonine, or valine, all of which are metabolized via the methylmalonyl CoA pathway (",
"    <a class=\"graphic graphic_figure graphicRef53127 \" href=\"UTD.htm?32/14/33005\">",
"     figure 1",
"    </a>",
"    ). Dietary protein is increased gradually, taking into account age, weight, metabolic control, and plasma levels of essential amino acids. However, no plasma amino acid concentration exists that can be used as a metabolic marker in MMA, as is the case, for example, in maple syrup urine disease. Serial measurements of plasma MMA concentrations may be helpful to guide management.",
"   </p>",
"   <p>",
"    The intake of odd-chain fatty acids (also metabolized by the methylmalonyl CoA pathway) and polyunsaturated fat is restricted. Intralipid contains even-chain fatty acids, and therefore, can be given to supply additional calories in infants dependent upon parenteral nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydroxy-cobalamin (1 mg per day IM) is given until the type of MMA is known. Infants with defects in the synthesis of adenosylcobalamin often respond to this treatment, whereas those with mutase defects do not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Broad-spectrum antibiotics are used to suppress bacteria in the gastrointestinal tract that contribute to the synthesis of organic acids (eg, propionic acid) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A short course (two to four months) of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    (10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day every eight hours IV or PO) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    , which is not absorbed (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day four times daily PO), can be given. These antibiotics may be especially helpful during episodes of metabolic decompensation. Short courses of antibiotic treatment may be repeated up to three to four times per year.",
"   </p>",
"   <p>",
"    In patients with combined MMA and homocystinuria, additional medications are given to enhance the remethylation of homocysteine to methionine. We use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23459?source=see_link\">",
"     betaine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO q12 hours) and folate (15",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    or 50 microgram total, 0.1 to 0.3 mg total, or 0.5 mg total PO per day in infants, children, and adults, respectively).",
"   </p>",
"   <p>",
"    Therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/49/38675?source=see_link\">",
"     carglumic acid",
"    </a>",
"    may be considered in cases of MMA when significant hyperammonemia (eg, &gt;400",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/14\">",
"     14",
"    </a>",
"    ]. Carglumic acid, a molecular analogue, may reduce hyperammonemia through direct activation of carbamoyl phosphate synthetase 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MMA can die in the newborn period or during a later episode of metabolic decompensation. Those who survive often have significant neurodevelopmental handicap, although normal cognitive development can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/16\">",
"     16",
"    </a>",
"    ]. Brain CT and MRI demonstrate widening of sulci and fissures, delayed myelination, and involvement of basal ganglia and white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal disease, which may result in chronic renal failure, can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,26-29\">",
"     1,26-29",
"    </a>",
"    ]. It is thought to be caused by tubulointerstitial injury that may be caused by methylmalonyl-CoA or its precursors, or possibly uric acid nephropathy. Other complications that may occur include pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/30\">",
"     30",
"    </a>",
"    ], cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/31\">",
"     31",
"    </a>",
"    ], recurrent infections that may be related to neutropenia, and hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,32\">",
"     1,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver or combined liver and kidney transplantation has been attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The underlying biochemical parameters and the frequency of metabolic decompensation improve significantly despite persistent metabolic abnormalities. However, perioperative mortality is high, and despite apparent correction of the biochemical defect in the liver, neurologic complications are frequent. Overall, the long-term outcome is not yet determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROPIONIC ACIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with methylmalonyl CoA, propionyl CoA is formed through the catabolism of isoleucine, valine, threonine, methionine, odd-chain fatty acids, thymidine, uracil, and cholesterol (",
"    <a class=\"graphic graphic_figure graphicRef53127 \" href=\"UTD.htm?32/14/33005\">",
"     figure 1",
"    </a>",
"    ). In addition, a significant amount of propionyl CoA may be generated by gut bacteria.",
"   </p>",
"   <p>",
"    Propionic acidemia (PA) is caused by a deficiency of propionyl-CoA carboxylase, a dimer of two different subunits (alpha chain on chromosome 13q32 and beta chain on chromosome 3q13.3). Numerous mutations have been identified in the genes encoding both chains in patients with PA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Prenatal diagnosis is available through measurement of enzyme activity in cultured amniotic fluid cells or chorionic villi cells, or measurement of methylcitric acid or propionylcarnitine in amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. PA occurs in approximately 1 in 100,000 newborns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients typically present in the neonatal period with the signs of organic acidemia, although a few present at an older age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. Some patients have hepatomegaly or develop seizures. Presentation of less severe forms of the disease may occur in older children or adults with episodes of vomiting and lethargy, failure to thrive, protein intolerance, seizures, or psychomotor abnormalities, such as floppiness and hypotonia. Conduction abnormalities and cardiomyopathy may occur; electrocardiograms and echocardiography should be performed regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. In one review of 10 children with PA who were evaluated with electrocardiogram, exercise testing, and echocardiography, the QTc interval was prolonged (&gt;440 ms) in seven, and four had reduced left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/39\">",
"     39",
"    </a>",
"    ]. Regular cardiac evaluation is warranted, because prolonged QTc in patients with PA may lead to life-threatening events [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatitis has been reported in PA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/42\">",
"     42",
"    </a>",
"    ]. Some infants with PA have dysmorphic facial features similar to those of MMA (high forehead; broad nasal bridge; epicanthal folds; long, smooth philtrum; and triangular mouth). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Methylmalonic aciduria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of organic acids in the urine by GC-MS shows high concentrations of metabolites of propionyl-CoA, including propionic acid, methylcitrate, 3-OH propionic acid, tiglic acid, tiglylglycine, and propionylglycine. Quantitative measurements of amino acids in plasma and urine typically show increased glycine concentration, which results from inhibition of the synthesis of the glycine cleavage enzyme by propionyl-CoA, leading to reduced glycine oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. However, glycine values can be normal, even in an infant with previously abnormal levels. High ammonia concentrations, similar to those seen in urea cycle disorders, can be seen and may be secondary to inhibition of N-acetylglutamate synthesis through accumulating propionyl-CoA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3618775\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn screening for PA is performed in several European countries as well as all states in the United States. A study comparing the outcomes of patients with PA that were diagnosed by selective metabolic screening with those diagnosed through newborn screening demonstrated that there was little difference in outcomes between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/44\">",
"     44",
"    </a>",
"    ]. Early diagnosis was associated with lower mortality, but no decrease in morbidity in long-term survivors.",
"   </p>",
"   <p>",
"    Plasma concentrations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    are reduced, and acylcarnitine profiles show increased levels of propionylcarnitine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/13\">",
"     13",
"    </a>",
"    ]. Demonstration of deficient activity of propionyl-CoA carboxylase in skin fibroblasts or peripheral blood leukocytes establishes a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment for PA consists of a low-protein diet containing the minimum natural protein required for growth. Restriction to 8 to 12 g per day is recommended for the first three years, with a slow increase to 15 to 20 g per day by six to eight years of age, taking into account weight, metabolic control, and plasma levels of essential amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/36\">",
"     36",
"    </a>",
"    ]. The diet usually is supplemented with an amino acid mixture that",
"    <strong>",
"     does not contain",
"    </strong>",
"    isoleucine, methionine, threonine, or valine to provide up to 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of total protein. The intake of odd-chain fatty acids and polyunsaturated fat also is restricted.",
"   </p>",
"   <p>",
"    Gastrostomy tube placement may be indicated, particularly when feeding is difficult",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when the",
"    <span class=\"nowrap\">",
"     infant/child",
"    </span>",
"    with PA is at risk for frequent episodes of metabolic decompensation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents and caretakers should be taught how to recognize early signs of metabolic decompensation, how to increase fluid and energy intake while at home, and when to take the individual with PA to an emergency department. The treating metabolic specialist needs to provide a letter detailing the emergency regimen on how to treat PA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    (5 to 10 mg per day orally), an essential cofactor, may be initiated and the patient observed for a biochemical response. However, only one patient with biotin-responsive PA has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,47\">",
"     1,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with MMA, antibiotics can be used to suppress gut bacteria and reduce propionic acid production. Bicarbonate is given to treat persistent metabolic acidosis, which can impair growth in children.",
"   </p>",
"   <p>",
"    Therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/49/38675?source=see_link\">",
"     carglumic acid",
"    </a>",
"    may be considered in cases of MMA and PA when significant hyperammonemia (eg, &gt;400",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/14\">",
"     14",
"    </a>",
"    ]. Carglumic acid, a molecular analogue, may reduce hyperammonemia through direct activation of carbamoyl phosphate synthetase 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16103169\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation has been performed in a few patients with frequent and severe episodes of metabolic decompensation despite good dietary therapy or previous sibling death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In one series, all five transplanted children had sustained normal graft function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/48\">",
"     48",
"    </a>",
"    ]. One child had a single metabolic event posttransplantation. The patients otherwise had no metabolic decompensations on a protein-unrestricted diet. Auxiliary liver transplantation is an alternative approach to orthotopic liver transplantation that preserves the native liver [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to those with MMA, patients severely affected with PA can die in the newborn period or during a later episode of metabolic decompensation. Significant neurodevelopmental handicap occurs often in those who survive, although some patients have normal cognitive development [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/16\">",
"     16",
"    </a>",
"    ]. Seizures may occur, and acute basal ganglia infarction has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other complications include recurrent hypoglycemia; infection, including moniliasis; and osteoporosis with secondary fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,32,52\">",
"     1,32,52",
"    </a>",
"    ]. The mechanism of osteoporosis is not known. Pancreatitis may be a complication of organic acidemias and should be considered if patients develop abdominal pain, vomiting, encephalopathy, or shock [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are individuals identified through newborn screening who have mild biochemical abnormalities and remain asymptomatic. The clinical outcomes of this group of patients are yet unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ISOVALERIC ACIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isovaleric acidemia (IVA) is caused by a deficiency of isovaleryl-CoA dehydrogenase, the enzyme that converts isovaleryl-CoA to 3-methylcrotonyl CoA in the breakdown pathway of leucine (",
"    <a class=\"graphic graphic_figure graphicRef65861 \" href=\"UTD.htm?12/8/12430\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. Isovaleryl-CoA dehydrogenase is a mitochondrial flavoenzyme, and specific mutations have been identified in patients with IVA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVA typically presents in the neonatal period with signs of organic acidemia. In addition, the accumulation of isovaleric acid results in the characteristic odor described as \"sweaty feet\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. Some patients present later in the first year with vomiting, ketoacidosis, lethargy, and coma. IVA rarely is identified in children who develop pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of organic acids in urine by GC-MS demonstrates increased concentrations of oxidation and conjugation products of isovaleric acid, including isovalerylglycine and 3-hydroxyisovaleric acid. Acylcarnitine profiles show increased levels of isovaleryl-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    . Elevated ammonia levels may initially suggest a urea cycle disorder. Demonstration of deficient activity of isovaleryl-CoA dehydrogenase in skin fibroblasts or peripheral blood leukocytes confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment of IVA consists of a low-protein diet containing the minimum natural protein required for growth. As with MMA and PA, the protein intake is increased gradually as tolerated depending on age, growth, development, metabolic control, and plasma levels of essential amino acids. The diet usually is supplemented with an amino acid mixture that",
"    <strong>",
"     does not contain",
"    </strong>",
"    leucine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycine (250",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in three doses PO) is given to enhance the formation and excretion of isovalerylglycine. It is given in addition to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (100 to 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV or 100 to 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in three doses PO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVA has a better prognosis than do MMA and PA, and the majority of children who survive develop normally [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. However, an estimated one-half of patients who present in the newborn period do not survive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     3-METHYLCROTONYLGLYCINURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    -resistant 3-methylcrotonylglycinuria (3-MCG, also known as 3-methylcrotonyl CoA carboxylase deficiency) is caused by a deficiency of 3-methylcrotonyl CoA carboxylase (MCC), which catalyzes the conversion of 3-methylcrotonyl CoA to 3-methylglutaconyl CoA in the catabolic pathway of leucine (",
"    <a class=\"graphic graphic_figure graphicRef65861 \" href=\"UTD.htm?12/8/12430\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,55\">",
"     1,55",
"    </a>",
"    ]. MCC is a biotin-dependent carboxylase that belongs to the same group of enzymes as do propionyl CoA carboxylase, pyruvate carboxylase, and acetyl CoA carboxylase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/55\">",
"     55",
"    </a>",
"    ]. 3-MCG is one of the most common organic acidemias detected by tandem mass spectrometry in newborn screening programs. It occurs in approximately 1 in 50,000 newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MCC deficiency also can result from multiple carboxylase deficiency secondary to a deficiency of holocarboxylase synthetase or biotinidase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to 3-MCG, these disorders are",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    responsive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with 3-MCG may present between six months and three years of age with a clinical picture similar to that of Reye syndrome. Symptoms may include lethargy, feeding difficulties, vomiting, seizures, muscular hypotonia, and hyperreflexia. During an episode of metabolic decompensation, patients can have severe hypoglycemia, hyperammonemia, mild metabolic acidosis with ketonuria, and elevated serum transaminase concentrations.",
"   </p>",
"   <p>",
"    Less frequently, affected newborns develop a fatal illness characterized by seizures and muscular hypotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients also may present later in childhood during an episode of increased catabolism, such as an intercurrent illness. Many patients diagnosed on newborn screening are found to remain healthy, and a number of healthy affected mothers have also been ascertained through newborn screening. This raises the question of whether 3-MCC deficiency constitutes a disease or merely a biochemical phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine is increased during an acute episode. Total and free plasma",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    levels are reduced, with elevated concentration of 3-hydroxyisovalerylcarnitine. If MCC deficiency is secondary to multiple carboxylase deficiency, urinary excretion of 3-methylcitrate, propionic acid, and propionylcarnitine is increased.",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by measurement of deficient MCC activity in leukocytes or fibroblasts. This technique also will demonstrate deficiency of a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    -dependent carboxylase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consensus has yet been reached for the treatment in patients with 3-MCG [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/60\">",
"     60",
"    </a>",
"    ]. Most patients do well with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation only, without developing decompensation. For symptomatic patients, specific treatment similar to that for IVA and a low-protein diet containing the minimum natural protein required for growth is an option if the symptoms are felt to be due to 3-MCC deficiency rather than some other cause (eg, multiple carboxylase deficiency or secondary carnitine deficiency).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific medication is available for treatment of 3-MCG.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     Biotin",
"    </a>",
"    (5 to 10 mg per day, independent of age) is given until the possibility of multiple carboxylase deficiency is excluded.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     L-carnitine",
"    </a>",
"    is recommended when the free",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    is deficient. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with this disorder will have a good outcome with normal neurodevelopment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19254287\">",
"    <span class=\"h1\">",
"     3-METHYLGLUTACONIC ACIDURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five known types of 3-methylglutaconic aciduria (MGA):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MGA type I is a rare autosomal recessive organic aciduria caused by deficiency of 3-methylglutaconyl-CoA hydratase, an enzyme in the leucine degradation pathway converting 3-methylglutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA. As a consequence, patients with MGA type I excrete increased amounts of 3-methylglutaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid. The clinical spectrum ranges from asymptomatic infants diagnosed through expanded newborn screening to adults with progressive neurodegeneration. Less than 20 patients with MGA type I have been reported in the literature [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MGA type II (Barth syndrome) is an X-linked disorder due to mutations in the",
"      <em>",
"       TAZ",
"      </em>",
"      gene that encodes tafazzin. The phospholipid acyltransferase activity of tafazzin is responsible for remodeling of cardiolipin, an important component of the inner mitochondrial membrane and respiratory chain activity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/62\">",
"       62",
"      </a>",
"      ]. Clinical symptoms of Barth Syndrome include cardiomyopathy (dilated, isolated noncompaction of the ventricular myocardium), neutropenia, skeletal myopathy, and growth delay. Phenotypic variability may be marked even within the same family [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/63\">",
"       63",
"      </a>",
"      ]. Barth syndrome is usually suspected on the basis of clinical symptoms and a positive family history. Elevated 3-methylglutaconic acid (3-MGA) excretion in urine further supports the diagnosis; however, the absence of this finding does not rule out the disorder. Tetralinoleoyl-cardiolipin levels are low in individuals with Barth syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/64\">",
"       64",
"      </a>",
"      ], although this test is only available in a few specialized diagnostic laboratories. Management is supportive only, with the main focus on treatment of cardiomyopathy and neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MGA type III (Costeff syndrome) is a rare neuroophthalmologic syndrome associated with early onset optic atrophy, neurologic symptoms, cognitive impairment, and 3-MGA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/65\">",
"       65",
"      </a>",
"      ]. Mutations in the",
"      <em>",
"       OPA3",
"      </em>",
"      gene are causative.",
"     </li>",
"     <li>",
"      MGA type IV is a heterogeneous group of patients with intermittent 3-MGA who do not have an identified defect.",
"     </li>",
"     <li>",
"      MGA type V is characterized by dilated cardiomyopathy in combination with ataxia and 3-MGA in individuals of Canadian Dariusleut Hutterite ethnicity. It is due to mutations in the",
"      <em>",
"       DNAJC19",
"      </em>",
"      gene that encodes a protein involved in import of other proteins into the mitochondria [",
"      <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     GLUTARIC ACIDURIA TYPE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutaric aciduria (or acidemia) type 1 (GA1) is caused by deficiency of riboflavin-dependent glutaryl-CoA dehydrogenase (GCDH), the mitochondrial enzyme that converts glutaryl-CoA to crotonyl-CoA in the catabolic pathway of lysine, hydroxylysine, and tryptophan (",
"    <a class=\"graphic graphic_algorithm graphicRef51027 \" href=\"UTD.htm?39/50/40748\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. A variety of mutations have been identified in the glutaryl-CoA dehydrogenase gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/67\">",
"     67",
"    </a>",
"    ]. In a mouse model, expression of GCDH in the brain was limited to neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Scandinavian study estimated the frequency as 1 in 30,000 newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/69\">",
"     69",
"    </a>",
"    ]. The prevalence is increased among North American aboriginals (Ojibway-Cree) in northeastern Manitoba and northwestern Ontario [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/70\">",
"     70",
"    </a>",
"    ] and among the Amish in Pennsylvania.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the other organic acidurias, GA1 rarely presents in the newborn period. Affected children typically have an episode of metabolic decompensation with ketoacidosis, hyperammonemia, hypoglycemia, and encephalopathy during the first year or later, often accompanied by infection and fever; they also develop a dystonic movement disorder with preserved cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,71-73\">",
"     1,71-73",
"    </a>",
"    ]. Many infants have feeding difficulties because of orofacial dyskinesia.",
"   </p>",
"   <p>",
"    In a series of 77 affected patients, decompensation occurred before 18 months of age, almost always during an infectious illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/74\">",
"     74",
"    </a>",
"    ]. The decompensation was associated with acute symmetric striatal necrosis, similar to a stroke in time course, radiologic appearance, and irreversibility, and resulting in dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Injury to the putamen was associated with sudden developmental arrest.",
"   </p>",
"   <p>",
"    In a mouse model, pathologic changes were evident within 24 to 48 hours of lysine exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/68\">",
"     68",
"    </a>",
"    ]. Lysine accumulation was enhanced in immature mice, permitting increased glutaric acid production and a possible explanation for the age-dependent injury.",
"   </p>",
"   <p>",
"    Patients typically have microencephalic macrocephaly; when present at birth, it is the earliest sign of GA1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/74\">",
"     74",
"    </a>",
"    ]. In some patients, the head circumference is normal at birth, but increases rapidly during infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1,73\">",
"     1,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link\">",
"     \"Etiology and evaluation of macrocephaly in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 percent of children have seizures, and 20 to 30 percent have subdural hemorrhages or effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/70,76\">",
"     70,76",
"    </a>",
"    ]. Other symptoms include insomnia, hyperthermia, hyperhidrosis, and anorexia.",
"   </p>",
"   <p>",
"    The presentation of GA1 is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/70,77\">",
"     70,77",
"    </a>",
"    ] and appears to be unrelated to biochemical phenotype or genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/78\">",
"     78",
"    </a>",
"    ]. Episodes of decompensation and encephalopathy are mild or absent in approximately 25 percent of affected children. These patients develop dystonia that often is diagnosed as cerebral palsy and have motor delay and intellectual disability (mental retardation) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/71\">",
"     71",
"    </a>",
"    ]. Some children present with acute subdural hemorrhage or chronic subdural effusions that may be mistakenly attributed to child abuse or shaken baby syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/71,79-81\">",
"     71,79-81",
"    </a>",
"    ]. A possible mechanism of the acute hemorrhage is increased fragility of bridging veins that are stretched because of cerebral atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autopsy studies confirm the presence of macroencephaly and striatal atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/82-89\">",
"     82-89",
"    </a>",
"    ]. In one autopsy series of six patients ranging in age from 8 months to 40 years, the neuron loss appeared to occur shortly after the encephalopathic episode and to be nonprogressive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, all brain regions, not just the striatum, demonstrated markedly elevated concentrations of glutaric acid. This finding suggests that brain injury may be related to the efficiency of organic acid clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary concentrations of glutaric acid and 3-hydroxyglutaric acid are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/91\">",
"     91",
"    </a>",
"    ]. Excretion of glutaconic acid and dicarboxylic acids may be more prominent than that of 3-hydroxyglutaric acid during episodes of ketosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/92\">",
"     92",
"    </a>",
"    ]. Plasma concentrations of glutarylcarnitine (C5DC) are increased, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    levels are low.",
"   </p>",
"   <p>",
"    Glutaryl-CoA dehydrogenase activity measured in leukocytes or fibroblasts is deficient. A large number of mutations have been identified using molecular techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment for GA1 consists of a low-protein diet containing the minimum natural protein required for growth [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/91\">",
"     91",
"    </a>",
"    ]. Similar to that of the other organic acidemias, the protein intake is increased gradually as tolerated depending on age, growth, development, and plasma levels of essential amino acids. The diet usually is supplemented with an amino acid mixture that does not contain tryptophan and lysine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Riboflavin (100 to 300 mg per day) is given in addition to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (100 to 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV or 100 to 300",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in three doses PO). Riboflavin is a cofactor of glutaryl-CoA dehydrogenase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment for the dystonia may include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    or valproic acid.",
"   </p>",
"   <p>",
"    In a mouse model, administration of homoarginine (to limit lysine uptake) and glucose (to limit lysine catabolism) reduced brain glutaric acid accumulation, improved survival, and prevented brain injury in surviving animals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/68\">",
"     68",
"    </a>",
"    ]. Treatment success correlated directly with control of brain glutaric acid levels and maintenance of glutamate and gamma amino butyric acid (GABA). Depletion of glutamate and GABA (a marker for impending brain injury) was detectable with proton magnetic resonance spectroscopy. These findings may facilitate the development of improved treatment and monitoring strategies for patients with GA1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are undiagnosed and untreated develop cerebral atrophy with developmental delay and pyramidal tract signs (brisk deep tendon reflexes, spastic tone, and extensor plantar response). Neuroimaging studies typically show extracerebral fluid collections and atrophy in the frontotemporal regions and diffuse hypodensities in the white matter; these may improve with dietary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/94\">",
"     94",
"    </a>",
"    ]. Some children with GA1 can develop normally if they are treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     L-carnitine",
"    </a>",
"    and a low protein diet when initially diagnosed and episodes of metabolic decompensation are avoided during intercurrent illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/46/7914/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organic acidemias, also known as organic acidurias, are a group of disorders characterized by increased excretion of organic acids in urine. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborns with organic acidemia typically present during the first one to two weeks after birth with poor feeding, vomiting, increasing lethargy, hypotonia, and metabolic acidosis with increased anion gap. Older infants and children may present with lethargy, vomiting, failure to thrive, seizures, or acute metabolic decompensation associated with an intercurrent illness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of an infant with suspected organic acidemia includes measurement of pH, carbon dioxide tension, ammonia, lactate, pyruvate, glucose, electrolytes, creatinine, urea, ketones, and complete blood count. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory features of organic acidemia include severe metabolic acidosis with an increased anion gap, ketosis, and hyperammonemia. Other findings may include hypoglycemia; electrolyte and other abnormalities associated with dehydration; and evidence of bone marrow suppression. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific organic acidemias are suggested by measurement of organic acids in the urine and confirmed by demonstration of deficient enzyme activity in skin fibroblasts or peripheral blood leukocytes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Methylmalonic aciduria &mdash; Increased urinary methylmalonic acid, methylcitrate, propionic acid, and 3-OH propionic acid (",
"      <a class=\"graphic graphic_figure graphicRef53127 \" href=\"UTD.htm?32/14/33005\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Methylmalonic aciduria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Propionic acidemia &mdash; Increased urinary propionic acid, methylcitrate, 3-OH propionic acid, tiglic acid, tiglylglycine, and propionylglycine (",
"      <a class=\"graphic graphic_figure graphicRef53127 \" href=\"UTD.htm?32/14/33005\">",
"       figure 1",
"      </a>",
"      ); deficient activity of propionyl-CoA carboxylase. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Propionic acidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isovaleric acidemia &mdash; Increased urinary isovalerylglycine and 3-hydroxyisovaleric acid (",
"      <a class=\"graphic graphic_figure graphicRef65861 \" href=\"UTD.htm?12/8/12430\">",
"       figure 2",
"      </a>",
"      ); deficient activity of isovaleryl-CoA dehydrogenase. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Isovaleric acidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      3-Methylcrotonylglycinuria &mdash; Increased urinary 3-hydroxyisovaleric acid and 3-methylcrotonylglycine (",
"      <a class=\"graphic graphic_figure graphicRef65861 \" href=\"UTD.htm?12/8/12430\">",
"       figure 2",
"      </a>",
"      ); deficient activity of 3-methylcrotonyl CoA carboxylase. (See",
"      <a class=\"local\" href=\"#H27\">",
"       '3-Methylcrotonylglycinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      3-Methylglutaconic aciduria &ndash; Increased urinary 3-methylglutaconic acid. (See",
"      <a class=\"local\" href=\"#H19254287\">",
"       '3-Methylglutaconic aciduria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glutaric aciduria type 1 &mdash; Increased urinary glutaric acid and 3-hydroxyglutaric acid (",
"      <a class=\"graphic graphic_algorithm graphicRef51027 \" href=\"UTD.htm?39/50/40748\">",
"       algorithm 1",
"      </a>",
"      ); deficient glutaryl-CoA dehydrogenase activity. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Glutaric aciduria type 1'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial management of organic acidemia includes withholding protein from the diet or parenteral nutrition; intravenous hydration; and correction of metabolic acidosis, hyperammonemia, hypoglycemia, and electrolyte abnormalities. Associated illnesses (eg, infections) also are treated. After one to two days of treatment, a specific low-protein diet that excludes the offending amino acids is gradually introduced. Medications may be given to reduce the formation or increase the excretion of toxic metabolites. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with organic acidemia are susceptible to metabolic decompensation during episodes of increased catabolism (eg, intercurrent illness, trauma, or surgery). Parents and clinicians must be educated about the initial signs of decompensation and trained in applying an emergency regimen. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Nyhan WL, Ozand PT. Atlas of Metabolic Diseases, 1st ed, Chapman and Hall Medical, London 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/2\">",
"      Morris AA, Leonard JV. Early recognition of metabolic decompensation. Arch Dis Child 1997; 76:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/3\">",
"      Dixon MA, Leonard JV. Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child 1992; 67:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/4\">",
"      Rashed MS, Rahbeeni Z, Ozand PT. Application of electrospray tandem mass spectrometry to neonatal screening. Semin Perinatol 1999; 23:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/5\">",
"      Fowler B, Giles L, Sardharwalla IB, et al. First trimester diagnosis of methylmalonic aciduria. Prenat Diagn 1988; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/6\">",
"      Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis 2007; 30:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/7\">",
"      Fowler B. Genetic defects of folate and cobalamin metabolism. Eur J Pediatr 1998; 157 Suppl 2:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/8\">",
"      Hoffmann GF, Zschocke J. Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. J Inherit Metab Dis 1999; 22:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/9\">",
"      Hoffmann GF, Gibson KM, Trefz FK, et al. Neurological manifestations of organic acid disorders. Eur J Pediatr 1994; 153:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/10\">",
"      Leonard JV, Morris AA. Inborn errors of metabolism around time of birth. Lancet 2000; 356:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/11\">",
"      Bier DM, Leake RD, Haymond MW, et al. Measurement of \"true\" glucose production rates in infancy and childhood with 6,6-dideuteroglucose. Diabetes 1977; 26:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/12\">",
"      Rajpoot DK, Gargus JJ. Acute hemodialysis for hyperammonemia in small neonates. Pediatr Nephrol 2004; 19:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/13\">",
"      Di Donato S, Rimoldi M, Garavaglia B, Uziel G. Propionylcarnitine excretion in propionic and methylmalonic acidurias: a cause of carnitine deficiency. Clin Chim Acta 1984; 139:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/14\">",
"      Levrat V, Forest I, Fouilhoux A, et al. Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia? Orphanet J Rare Dis 2008; 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     Fenton WA, Gravel RA, Rosenblatt DS. Disorders of propionate and methylmalonate metabolism. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.2165.",
"    </li>",
"    <li>",
"     Wappner RS. Disorders of amino acid and organic acid metabolism. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/17\">",
"      Miousse IR, Watkins D, Coelho D, et al. Clinical and molecular heterogeneity in patients with the cblD inborn error of cobalamin metabolism. J Pediatr 2009; 154:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/18\">",
"      Aminoff M, Carter JE, Chadwick RB, et al. Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. Nat Genet 1999; 21:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/19\">",
"      Coulombe JT, Shih VE, Levy HL. Massachusetts Metabolic Disorders Screening Program. II. Methylmalonic aciduria. Pediatrics 1981; 67:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/20\">",
"      Rosenblatt DS, Aspler AL, Shevell MI, et al. Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC). J Inherit Metab Dis 1997; 20:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/21\">",
"      Bodamer OA, Rosenblatt DS, Appel SH, Beaudet AL. Adult-onset combined methylmalonic aciduria and homocystinuria (cblC). Neurology 2001; 56:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/22\">",
"      Sniderman LC, Lambert M, Gigu&egrave;re R, et al. Outcome of individuals with low-moderate methylmalonic aciduria detected through a neonatal screening program. J Pediatr 1999; 134:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/23\">",
"      Thompson GN, Chalmers RA, Walter JH, et al. The use of metronidazole in management of methylmalonic and propionic acidaemias. Eur J Pediatr 1990; 149:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/24\">",
"      Koletzko B, Bachmann C, Wendel U. Antibiotic therapy for improvement of metabolic control in methylmalonic aciduria. J Pediatr 1990; 117:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/25\">",
"      Brismar J, Ozand PT. CT and MR of the brain in disorders of the propionate and methylmalonate metabolism. AJNR Am J Neuroradiol 1994; 15:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/26\">",
"      Molteni KH, Oberley TD, Wolff JA, Friedman AL. Progressive renal insufficiency in methylmalonic acidemia. Pediatr Nephrol 1991; 5:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/27\">",
"      Baumgarter ER, Viardot C. Long-term follow-up of 77 patients with isolated methylmalonic acidaemia. J Inherit Metab Dis 1995; 18:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/28\">",
"      Paik KH, Lee JE, Jin DK. Successful dialysis in a boy with methylmalonic acidemia. Pediatr Nephrol 2004; 19:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/29\">",
"      Schmitt CP, Mehls O, Trefz FK, et al. Reversible end-stage renal disease in an adolescent patient with methylmalonic aciduria. Pediatr Nephrol 2004; 19:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/30\">",
"      Kahler SG, Sherwood WG, Woolf D, et al. Pancreatitis in patients with organic acidemias. J Pediatr 1994; 124:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/31\">",
"      Prada CE, Al Jasmi F, Kirk EP, et al. Cardiac disease in methylmalonic acidemia. J Pediatr 2011; 159:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/32\">",
"      Ozand PT. Hypoglycemia in association with various organic and amino acid disorders. Semin Perinatol 2000; 24:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/33\">",
"      van't Hoff W, McKiernan PJ, Surtees RA, Leonard JV. Liver transplantation for methylmalonic acidaemia. Eur J Pediatr 1999; 158 Suppl 2:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/34\">",
"      van 't Hoff WG, Dixon M, Taylor J, et al. Combined liver-kidney transplantation in methylmalonic acidemia. J Pediatr 1998; 132:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/35\">",
"      Mc Guire PJ, Lim-Melia E, Diaz GA, et al. Combined liver-kidney transplant for the management of methylmalonic aciduria: a case report and review of the literature. Mol Genet Metab 2008; 93:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/36\">",
"      Ugarte M, P&eacute;rez-Cerd&aacute; C, Rodr&iacute;guez-Pombo P, et al. Overview of mutations in the PCCA and PCCB genes causing propionic acidemia. Hum Mutat 1999; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/37\">",
"      Kraus JP, Spector E, Venezia S, et al. Mutation analysis in 54 propionic acidemia patients. J Inherit Metab Dis 2012; 35:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/38\">",
"      Mardach R, Verity MA, Cederbaum SD. Clinical, pathological, and biochemical studies in a patient with propionic acidemia and fatal cardiomyopathy. Mol Genet Metab 2005; 85:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/39\">",
"      Baumgartner D, Scholl-B&uuml;rgi S, Sass JO, et al. Prolonged QTc intervals and decreased left ventricular contractility in patients with propionic acidemia. J Pediatr 2007; 150:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/40\">",
"      Jameson E, Walter J. Cardiac arrest secondary to long QT(C )in a child with propionic acidemia. Pediatr Cardiol 2008; 29:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/41\">",
"      Romano S, Valayannopoulos V, Touati G, et al. Cardiomyopathies in propionic aciduria are reversible after liver transplantation. J Pediatr 2010; 156:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/42\">",
"      Bultron G, Seashore MR, Pashankar DS, Husain SZ. Recurrent acute pancreatitis associated with propionic acidemia. J Pediatr Gastroenterol Nutr 2008; 47:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/43\">",
"      Gebhardt B, Dittrich S, Parbel S, et al. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. J Inherit Metab Dis 2005; 28:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/44\">",
"      Gr&uuml;nert SC, M&uuml;llerleile S, de Silva L, et al. Propionic acidemia: neonatal versus selective metabolic screening. J Inherit Metab Dis 2012; 35:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/45\">",
"      Sutton VR, Chapman KA, Gropman AL, et al. Chronic management and health supervision of individuals with propionic acidemia. Mol Genet Metab 2012; 105:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/46\">",
"      Chapman KA, Gropman A, MacLeod E, et al. Acute management of propionic acidemia. Mol Genet Metab 2012; 105:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/47\">",
"      Hillman RE, Keating JP, Williams JC. Biotin-responsive propionic acidemia presenting as the rumination syndrome. J Pediatr 1978; 92:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/48\">",
"      Vara R, Turner C, Mundy H, et al. Liver transplantation for propionic acidemia in children. Liver Transpl 2011; 17:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/49\">",
"      Saudubray JM, Touati G, Delonlay P, et al. Liver transplantation in propionic acidaemia. Eur J Pediatr 1999; 158 Suppl 2:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/50\">",
"      Rela M, Battula N, Madanur M, et al. Auxiliary liver transplantation for propionic acidemia: a 10-year follow-up. Am J Transplant 2007; 7:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/51\">",
"      Haas RH, Marsden DL, Capistrano-Estrada S, et al. Acute basal ganglia infarction in propionic acidemia. J Child Neurol 1995; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/52\">",
"      Talbot JC, Gummerson NW, Kluge W, et al. Osteoporotic femoral fracture in a child with propionic acidaemia presenting as non-accidental injury. Eur J Pediatr 2006; 165:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/53\">",
"      Ensenauer R, Vockley J, Willard JM, et al. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet 2004; 75:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/54\">",
"      Mohsen AW, Anderson BD, Volchenboum SL, et al. Characterization of molecular defects in isovaleryl-CoA dehydrogenase in patients with isovaleric acidemia. Biochemistry 1998; 37:10325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/55\">",
"      Baumgartner MR, Almashanu S, Suormala T, et al. The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency. J Clin Invest 2001; 107:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/56\">",
"      Naylor EW, Chace DH. Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 1999; 14 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/57\">",
"      Bannwart C, Wermuth B, Baumgartner R, et al. Isolated biotin-resistant deficiency of 3-methylcrotonyl-CoA carboxylase presenting as a clinically severe form in a newborn with fatal outcome. J Inherit Metab Dis 1992; 15:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/58\">",
"      Gibson KM, Bennett MJ, Naylor EW, Morton DH. 3-Methylcrotonyl-coenzyme A carboxylase deficiency in Amish/Mennonite adults identified by detection of increased acylcarnitines in blood spots of their children. J Pediatr 1998; 132:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/59\">",
"      Niu DM, Chien YH, Chiang CC, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis 2010; 33:S295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/60\">",
"      Arnold GL, Koeberl DD, Matern D, et al. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 2008; 93:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/61\">",
"      Mercimek-Mahmutoglu S, Tucker T, Casey B. Phenotypic heterogeneity in two siblings with 3-methylglutaconic aciduria type I caused by a novel intragenic deletion. Mol Genet Metab 2011; 104:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/62\">",
"      Takeda A, Sudo A, Yamada M, et al. Eponym: Barth syndrome. Eur J Pediatr 2011; 170:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/63\">",
"      Spencer CT, Bryant RM, Day J, et al. Cardiac and clinical phenotype in Barth syndrome. Pediatrics 2006; 118:e337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/64\">",
"      Kulik W, van Lenthe H, Stet FS, et al. Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome. Clin Chem 2008; 54:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/65\">",
"      Anikster Y, Kleta R, Shaag A, et al. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet 2001; 69:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/66\">",
"      Davey KM, Parboosingh JS, McLeod DR, et al. Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition. J Med Genet 2006; 43:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/67\">",
"      Schwartz M, Christensen E, Superti-Furga A, Brandt NJ. The human glutaryl-CoA dehydrogenase gene: report of intronic sequences and of 13 novel mutations causing glutaric aciduria type I. Hum Genet 1998; 102:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/68\">",
"      Zinnanti WJ, Lazovic J, Housman C, et al. Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type I. J Clin Invest 2007; 117:3258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/69\">",
"      Kyllerman M, Steen G. Glutaric aciduria. A \"common\" metabolic disorder? Arch Fr Pediatr 1980; 37:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/70\">",
"      Haworth JC, Booth FA, Chudley AE, et al. Phenotypic variability in glutaric aciduria type I: Report of fourteen cases in five Canadian Indian kindreds. J Pediatr 1991; 118:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/71\">",
"      Hartley LM, Khwaja OS, Verity CM. Glutaric aciduria type 1 and nonaccidental head injury. Pediatrics 2001; 107:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/72\">",
"      Hoffmann GF, Trefz FK, Barth PG, et al. Glutaryl-coenzyme A dehydrogenase deficiency: a distinct encephalopathy. Pediatrics 1991; 88:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/73\">",
"      Gordon N. Glutaric aciduria types I and II. Brain Dev 2006; 28:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/74\">",
"      Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet 2003; 121C:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/75\">",
"      Strauss KA, Morton DH. Type I glutaric aciduria, part 2: a model of acute striatal necrosis. Am J Med Genet C Semin Med Genet 2003; 121C:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/76\">",
"      Hoffmann GF, Athanassopoulos S, Burlina AB, et al. Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency. Neuropediatrics 1996; 27:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/77\">",
"      Zafeiriou DI, Zschocke J, Augoustidou-Savvopoulou P, et al. Atypical and variable clinical presentation of glutaric aciduria type I. Neuropediatrics 2000; 31:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/78\">",
"      Christensen E, Ribes A, Merinero B, Zschocke J. Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/79\">",
"      Bodamer O. Subdural hematomas and glutaric aciduria type I. Pediatrics 2001; 107:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/80\">",
"      Morris AA, Hoffmann GF, Naughten ER, et al. Glutaric aciduria and suspected child abuse. Arch Dis Child 1999; 80:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/81\">",
"      Forstner R, Hoffmann GF, Gassner I, et al. Glutaric aciduria type I: ultrasonographic demonstration of early signs. Pediatr Radiol 1999; 29:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/82\">",
"      K&ouml;lker S, Hoffmann GF, Schor DS, et al. Glutaryl-CoA dehydrogenase deficiency: region-specific analysis of organic acids and acylcarnitines in post mortem brain predicts vulnerability of the putamen. Neuropediatrics 2003; 34:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/83\">",
"      Goodman SI, Norenberg MD, Shikes RH, et al. Glutaric aciduria: biochemical and morphologic considerations. J Pediatr 1977; 90:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/84\">",
"      Leibel RL, Shih VE, Goodman SI, et al. Glutaric acidemia: a metabolic disorder causing progressive choreoathetosis. Neurology 1980; 30:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/85\">",
"      Chow CW, Haan EA, Goodman SI, et al. Neuropathology in glutaric acidaemia type 1. Acta Neuropathol 1988; 76:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/86\">",
"      Bergman I, Finegold D, Gartner JC Jr, et al. Acute profound dystonia in infants with glutaric acidemia. Pediatrics 1989; 83:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/87\">",
"      Soffer D, Amir N, Elpeleg ON, et al. Striatal degeneration and spongy myelinopathy in glutaric acidemia. J Neurol Sci 1992; 107:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/88\">",
"      Kimura S, Hara M, Nezu A, et al. Two cases of glutaric aciduria type 1: clinical and neuropathological findings. J Neurol Sci 1994; 123:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/89\">",
"      Funk CB, Prasad AN, Frosk P, et al. Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohort. Brain 2005; 128:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/90\">",
"      Strauss KA. Glutaric aciduria type 1: a clinician's view of progress. Brain 2005; 128:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/91\">",
"      K&ouml;lker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I--revised recommendations. J Inherit Metab Dis 2011; 34:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/92\">",
"      Gregersen N, Brandt NJ. Ketotic episodes in glutaryl-CoA dehydrogenase deficiency (glutaric aciduria). Pediatr Res 1979; 13:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/93\">",
"      Zschocke J, Quak E, Guldberg P, Hoffmann GF. Mutation analysis in glutaric aciduria type I. J Med Genet 2000; 37:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/94\">",
"      Cho CH, Mamourian AC, Filiano J, Nordgren RE. Glutaric aciduria: improved MR appearance after aggressive therapy. Pediatr Radiol 1995; 25:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/95\">",
"      Naughten ER, Mayne PD, Monavari AA, et al. Glutaric aciduria type I: outcome in the Republic of Ireland. J Inherit Metab Dis 2004; 27:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/46/7914/abstract/96\">",
"      Heringer J, Boy SP, Ensenauer R, et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol 2010; 68:743.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2927 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7914=[""].join("\n");
var outline_f7_46_7914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMMON FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      METHYLMALONIC ACIDURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROPIONIC ACIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3618775\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16103169\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ISOVALERIC ACIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      3-METHYLCROTONYLGLYCINURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19254287\">",
"      3-METHYLGLUTACONIC ACIDURIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      GLUTARIC ACIDURIA TYPE 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2927|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/50/40748\" title=\"algorithm 1\">",
"      Glutaric aciduria type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2927|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/14/33005\" title=\"figure 1\">",
"      Metabolic defects-methylmalonic aciduria and propionic acidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/8/12430\" title=\"figure 2\">",
"      Leucine degradation pathway and branched-chain organic acidemias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=related_link\">",
"      Etiology and evaluation of macrocephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/4/38983?source=related_link\">",
"      Micronutrient deficiencies associated with malnutrition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=related_link\">",
"      Physiology of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_46_7915="Causes of alveolar proteinosis";
var content_f7_46_7915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of alveolar proteinosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Pulmonary alveolar proteinosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute silicosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aluminum dust",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Titanium exposure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Viral",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Bacterial (eg, Nocardia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mycobacterial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Fungal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pneumocystis jirovecii pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leukemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Following allogeneic bone marrow transplantation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7915=[""].join("\n");
var outline_f7_46_7915=null;
var title_f7_46_7916="Increased T4 requirement";
var content_f7_46_7916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors that increase the requirement for T4",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Estrogen therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight gain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Drugs which increase catabolism of T4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Rifampin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Carbamazepine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Phenytoin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Phenobarbital",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Imatinib",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Malabsorption or increased excretion of T4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Gastrointestinal disorders (eg, celiac disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Impaired acid secretion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Drugs which interfere with T4 absorption",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Ferrous sulfate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Cholestyramine or colestipol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Sucralfate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Aluminum hydroxide gels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Calcium carbonate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Sertraline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Raloxifene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Omeprazole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Nephrotic syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Progressive thyroid dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Autoimmune thyroiditis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Previous thyroid irradiation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Roberts, CG, Ladenson, PW. Hypothyroidism. Lancet 2004; 363:793. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7916=[""].join("\n");
var outline_f7_46_7916=null;
var title_f7_46_7917="Acid load and NH4 excretion";
var content_f7_46_7917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dietary acid load increases ammonium excretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 229px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of a dietary acid load on the plasma bicarbonate concentration (dashed line, in meq/L) and urinary ammonium excretion (solid line, in meq/day) in normal subjects. Ammonium excretion increased almost four-fold despite a minimal fall in the plasma bicarbonate concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Welbourne, T, Weber, M, Bank, N, J Clin Invest 1972; 51:1852.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7917=[""].join("\n");
var outline_f7_46_7917=null;
var title_f7_46_7918="Causes nonfatal injury in children";
var content_f7_46_7918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    10 leading causes of nonfatal unintentional injury, United States, 2010, all races, both sexes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Rank",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Age groups, years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;1",
"       </td>",
"       <td class=\"subtitle2\">",
"        1-4",
"       </td>",
"       <td class=\"subtitle2\">",
"        5-9",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-14",
"       </td>",
"       <td class=\"subtitle2\">",
"        15-24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional fall",
"        </p>",
"        <p>",
"         146,804",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional fall",
"        </p>",
"        <p>",
"         970,793",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional fall",
"        </p>",
"        <p>",
"         649,460",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional fall",
"        </p>",
"        <p>",
"         627,418",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional struck by/against",
"        </p>",
"        <p>",
"         1,039,307",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional struck by/against",
"        </p>",
"        <p>",
"         32,933",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional struck by/against",
"        </p>",
"        <p>",
"         397,005",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional struck by/against",
"        </p>",
"        <p>",
"         421,482",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional struck by/against",
"        </p>",
"        <p>",
"         613,885",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional fall",
"        </p>",
"        <p>",
"         924,187",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other bite/sting",
"        </p>",
"        <p>",
"         11,937",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other bite/sting",
"        </p>",
"        <p>",
"         157,756",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional cut/pierce",
"        </p>",
"        <p>",
"         116,067",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional overexertion",
"        </p>",
"        <p>",
"         309,961",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional overexertion",
"        </p>",
"        <p>",
"         752,572",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional foreign body",
"        </p>",
"        <p>",
"         10,221",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional foreign body",
"        </p>",
"        <p>",
"         140,687",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other bite/sting",
"        </p>",
"        <p>",
"         101,982",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional cut/pierce",
"        </p>",
"        <p>",
"         137,375",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional MV-occupant",
"        </p>",
"        <p>",
"         741,398",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other specified",
"        </p>",
"        <p>",
"         9594",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional overexertion",
"        </p>",
"        <p>",
"         95,002",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional pedal cyclist",
"        </p>",
"        <p>",
"         82,145",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional pedal cyclist",
"        </p>",
"        <p>",
"         110,602",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional cut/pierce",
"        </p>",
"        <p>",
"         448,110",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional fire/burn",
"        </p>",
"        <p>",
"         8046",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional cut/pierce",
"        </p>",
"        <p>",
"         87,015",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional overexertion",
"        </p>",
"        <p>",
"         80,667",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional unknown/unspecified",
"        </p>",
"        <p>",
"         96,919",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other specified",
"        </p>",
"        <p>",
"         253,982",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional cut/pierce",
"        </p>",
"        <p>",
"         6891",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other specified",
"        </p>",
"        <p>",
"         73,524",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional MV-occupant",
"        </p>",
"        <p>",
"         65,611",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional MV-occupant",
"        </p>",
"        <p>",
"         82,439",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other bite/sting",
"        </p>",
"        <p>",
"         187,654",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional inhalation/suffocation",
"        </p>",
"        <p>",
"         6354",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional fire/burn",
"        </p>",
"        <p>",
"         52,367",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional foreign body",
"        </p>",
"        <p>",
"         61,816",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other bite/sting",
"        </p>",
"        <p>",
"         60,875",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional unknown/unspecified",
"        </p>",
"        <p>",
"         158,726",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional overexertion",
"        </p>",
"        <p>",
"         5849",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional poisoning",
"        </p>",
"        <p>",
"         43,939",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional dog bite",
"        </p>",
"        <p>",
"         42,199",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other transport",
"        </p>",
"        <p>",
"         48,822",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional poisoning",
"        </p>",
"        <p>",
"         133,613",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional MV-occupant",
"        </p>",
"        <p>",
"         5555",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional unknown/unspecified",
"        </p>",
"        <p>",
"         42,080",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other transport",
"        </p>",
"        <p>",
"         41,378",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional dog bite",
"        </p>",
"        <p>",
"         36,062",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unintentional other transport",
"        </p>",
"        <p>",
"         119,760",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MV: motor vehicle.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Injury prevention and control: Data and statistics (WISQARS). Available at:",
"     <a href=\"file://www.cdc.gov/injury/wisqars/index.html\" target=\"_blank\">",
"      www.cdc.gov/injury/wisqars/index.html",
"     </a>",
"     . Accessed on March 29, 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7918=[""].join("\n");
var outline_f7_46_7918=null;
var title_f7_46_7919="Arrangement of T cell receptor";
var content_f7_46_7919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Somatic rearrangements of the T cell receptor b chain germline DNA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 407px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The B chain of the T cell antigen receptor is composed of variable (V), diversity (D), and joining (J) segments. Somatic rearrangements occur with D-J joining followed by V-D-J joining. The random addition and/or deletion of nucleotides (N) forming the NDbN account for the tremendous diversity of the variable region of the b chain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from T cell maturation in the thymus. In: Cellular and Molecular Immunology, Abbas, AK, Lithtman, AH, Pober, JS, (Eds), Philadelphia, WB Saunders 1994. p.172.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_46_7919=[""].join("\n");
var outline_f7_46_7919=null;
